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  ﺒﺴﻡ ﺍﷲ ﺍﻟﺭﺤﻤﻥ ﺍﻟﺭﺤﻴﻡ
  ﺨﻼﺼﺔ ﺍﻟﺒﺤﺙ
  
ﺍﻟﺒﺤﺙ ﺍﻟﺫﻯ ﻴﺸﺘﻤل ﻋﻠﻰ ﺠﺯﺌﻴﻥ ، ﻓﻰ ﻤﺸﺭﻭﻉ ﺸﺭﻜﺔ ﺴﻜﺭ ﻜﻨﺎﻨﺔ ﺃﺠﺭﻯ ﻫﺫﺍ 
ﻡ  ﺒﺜﻼﺙ ﻤﺭﺍﻜﺯ ﺼﺤﻴﺔ ﻓﻰ ﺍﻟﻘﺭﻯ ﺍﻟﺯﺭﺍﻋﻴﺔ 6002 ﺍﻟﻰ 4002ﻓﻰ ﺍﻟﻔﺘﺭﺓ ﻤﻥ ﻋﺎﻡ 
 ﻟﺘﻘﻴﻴﻡ ﺩﺭﺠﺔ ﺤﺴﺎﺴﻴﺔ ﻁﻔﻴﻠﻰ ﺍﻟﻤﻼﺭﻴﺎ –ﺘﺎﺒﻌﺔ ﻟﻠﻤﺸﺭﻭﻉ ﻭﻤﺭﻜﺯ ﺼﺤﻰ ﺍﻟﻤﺼﻨﻊ 
  .ﻟﻠﻜﻠﻭﺭﻭﻜﻭﻴﻥ( ﺒﻼﺯﻤﻭﺩﻴﻭﻡ ﻓﺎﻟﺴﺒﺭﻡ)
ﺎﹰ ﺒﺎﻟﻤﻼﺭﻴﺎ ﺍﻟﺒﺴﻴﻁﺔ ، ﺸﺭﺍﺌﺤﻬﺎ  ﻤﺭﻴﻀ05ﺘﻭﺒﻌﺕ ﻓﻰ ﺍﻟﺠﺯﺀ ﺍﻷﻭل ﺤﺎﻟﺔ   
ﻤﻭﺠﺒﺔ ﻭﻤﻌﻠﻭﻡ ﺘﻌﺩﺍﺩ ﺍﻟﻁﻔﻴﻠﻰ ﺒﺎﻟﺸﺭﻴﺤﺔ ﻓﻰ ﻜل ﻤﺭﻜﺯ ﻤﻥ ﺍﻟﻤﺭﺍﻜﺯ ﺍﻷﺭﺒﻌﺔ ﻟﻴﺼﺒﺢ 
ﺤﺴﺏ ﺍﻟﻭﺯﻥ ﻭﺍﻟﻌﻤﺭ ﻭﺍﻟﺤﺎﻟﺔ ) ﻤﺭﻴﻀﺎﹰ ﻋﻭﻟﺠﻭﺍ ﺒﺎﻟﻜﻠﻭﺭﻭﻜﻭﻴﻥ 002ﺍﻟﻌﺩﺩ ﺍﻟﻜﻠﻰ 
  (.ﺍﻟﻌﺎﻤﺔ
ﻋﻤﺎﻟﺔ )ﻭﺍﻟﻤﺼﻨﻊ ( 6)ﻭﺍﻟﻘﺭﻴﺔ ( 3)ﻭﺍﻟﻘﺭﻴﺔ ( 2)ﺍﺨﺘﻴﺭﺕ ﻤﺭﺍﻜﺯ ﺍﻟﻘﺭﻴﺔ   
ﻻﻋﻁﺎﺀ ﺼﻭﺭﺓ ﻤﺘﻜﺎﻤﻠﺔ ﻟﻤﺭﺽ ﺍﻟﻤﻼﺭﻴﺎ، ﻤﻥ ﺤﻴﺙ ﺍﻟﺘﻭﺯﻴﻊ ( ﻨﺒﻴﺔﺴﻭﺩﺍﻨﻴﺔ ﻭﺃﺠ
ﺨﺭﺠﺕ ﺍﻟﺩﺭﺍﺴﺔ ﺒﺘﺤﺩﻴﺩ ﻨﺴﺒﺔ ﺍﺴﺘﺠﺎﺒﺔ ﻟﻠﻌﻼﺝ .  ﺍﻟﺴﻜﺎﻨﻰ ﻭﺍﻟﺠﻐﺭﺍﻓﻰ ﺒﺎﻟﻤﺸﺭﻭﻉ
  %.08ﺍﻟﻰ % 87ﺘﺘﺭﺍﻭﺡ ﺒﻴﻥ 
ﻜﻤﺎ ﺍﻟﻘﺕ ﺍﻟﺩﺭﺍﺴﺔ ﺍﻟﻀﻭﺀ ﻓﻰ ﻫﺫﺍ ﺍﻟﺠﺯﺀ ﻋﻠﻰ ﻨﺴﺒﺔ ﺇﻨﺘﺸﺎﺭ ﺍﻟﻤﻼﺭﻴﺎ ﻓﻰ   
% 51ﻭ % 82ﻭ % 73ﺴﺠﻠﺕ ﺍﻟﻘﺭﻯ ﺍﻟﺯﺭﺍﻋﻴﺔ ﻤﻘﺎﺭﻨﺔ ﺒﺎﻻﻤﺭﺍﺽ ﺍﻻﺨﺭﻯ ﺤﻴﺙ 
  . ﻤﻥ ﺠﻤﻠﺔ ﺍﻷﻤﺭﺍﺽ6002/5002/4002ﻓﻰ ﺍﻟﺴﻨﻭﺍﺕ 
ﻜﻤﺎ ﻗﺩﺭﺕ ﻨﺴﺒﺔ ﺍﻟﻭﻓﻴﺎﺕ ﻨﺘﻴﺠﺔ ﻟﻠﻤﻼﺭﻴﺎ ﻭﺍﻟﺘﻰ ﺘﺩﻨﺕ ﻤﻥ ﺴﻨﺔ   
  .ﺒﺎﻟﺘﺘﺎﻟﻰ% 0.0ﺍﻟﻰ % 41.0ﺍﻟﻰ % 79.0ﻡ ﻤﻥ 6002ﻡ ﺍﻟﻰ 5002/ﻡ4002
ﻜﻤﺎ ﻟﻭﺤﻅ ﻤﻥ ﺍﻟﺩﺭﺍﺴﺔ ﺃﻥ ﺤﺎﻻﺕ ﺍﻟﺸﺭﺍﺌﺢ ﺍﻟﻤﻭﺠﺒﺔ ﻻ ﻴﺘﻨﺎﺴﺏ ﻤﻊ ﻋﺩﺩ   
ﺘﺨﺘﺒﺭ ﻓﻰ ﺍﻟﻤﻌﻤل ﺤﻴﺙ ﺒﻠﻐﺕ ﻨﺴﺒﺔ ﺍﻟﺸﺭﺍﺌﺢ ﺍﻟﻤﻭﺠﺒﺔ ﻟﻌﺩﺩ ﺍﻟﺸﺭﺍﺌﺢ ﺍﻟﺸﺭﺍﺌﺢ ﺍﻟﺘﻰ 
% 32ﻓﻰ ﺍﻟﻜﻠﻴﻨﻙ ﻭ % 8ﻓﻰ ﺍﻟﻤﺴﺘﺸﻔﻰ % 31  ﻡ5002 /4002ﺍﻟﻜﻠﻰ ﻓﻰ ﺍﻟﺴﻨﻴﻥ 
  .ﻓﻰ ﻤﺭﻜﺯ ﺼﺤﻰ ﺍﻟﻤﺼﻨﻊ
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ﺃﻤﺎ ﺍﻟﺠﺯﺀ ﺍﻟﺜﺎﻨﻰ ﻓﻘﺩ ﻋﻨﻰ ﺒﺎﻷﺜﺭ ﺍﻻﻗﺘﺼﺎﺩﻯ ﻟﻤﺭﺽ ﺍﻟﻤﻼﺭﻴﺎ ﻋﻠﻰ ﺸﺭﻜﺔ ﺴﻜﺭ 
  . ﻟﻌﺎﻤﻠﻴﻬﺎ ﻭﺃﺴﺭﻫﻡ ﻤﺠﺎﻨﺎﹰﻜﻨﺎﻨﺔ ﺍﻟﺘﻰ ﺘﻘﺩﻡ ﺨﺩﻤﺎﺘﻬﺎ ﺍﻟﻌﻼﺠﻴﺔ
  : ﺍﻟﻘﻁﺎﻋﺎﺕ ﺍﻟﺴﻜﺎﻨﻴﺔ ﺍﻟﺜﻼﺜﺔ ﺍﻵﺘﻴﺔﻓﻲﺘﻭﺒﻌﺕ ﺤﺎﻻﺕ ﻤﺭﺽ ﺍﻟﻤﻼﺭﻴﺎ 
   ﺍﻟﻌﺎﻤﻠﻴﻥ ﺍﻟﻤﺼﺎﺒﻴﻥ ﺒﺎﻟﻤﻼﺭﻴﺎ ﺍﻟﻭﺨﻴﻤﺔ–ﺍﻟﻘﻁﺎﻉ ﺍﻟﻤﻨﺘﺞ  -
 . ﺃﺴﺭ ﺍﻟﻌﺎﻤﻠﻴﻥ ﺍﻟﻤﺼﺎﺒﻴﻥ ﺒﺎﻟﻤﻼﺭﻴﺎ ﺍﻟﻭﺨﻴﻤﺔ–ﺍﻟﻘﻁﺎﻉ ﻏﻴﺭ ﺍﻟﻤﻨﺘﺞ  -
  ﺍﺼﺎﺒﺎﺕ ﺒﺎﻟﻤﻼﺭﻴﺎ ﺍﻟﺒﺴﻴﻁﺔ–( ﺍﻟﻤﻨﺘﺞ ﻭﻏﻴﺭ ﺍﻟﻤﻨﺘﺞ)ﺍﻟﻘﻁﺎﻋﻴﻥ  -
  . ﻤﺭﻴﻀﺎﹰ05ﻭﻤﺜﻠﺕ ﻫﺫﻩ ﺍﻟﻘﻁﺎﻋﺎﺕ ﺒﻤﺠﻤﻭﻋﺎﺕ ﺸﻤﻠﺕ ﻜل ﻤﺠﻤﻭﻋﺔ 
  (ﺩﺨﻭﻻﺕ ﻤﺴﺘﺸﻔﻰ)ﻋﺎﻤﻠﻴﻥ :  ﺍﻟﻤﺠﻤﻭﻋﺔ ﺍﻻﻭﻟﻰ
  (ﺩﺨﻭﻻﺕ ﻤﺴﺘﺸﻔﻰ)ﺃﺴﺭ ﺍﻟﻌﺎﻤﻠﻴﻥ : ﺍﻟﻤﺠﻤﻭﻋﺔ ﺍﻟﺜﺎﻨﻴﺔ
  (ﻋﻴﺎﺩﺓ ﺨﺎﺭﺠﻴﺔ)ﺍﻟﻌﺎﻤﻠﻴﻥ ﻭﺃﺴﺭﻫﻡ :  ﺍﻟﻤﺠﻤﻭﻋﺔ ﺍﻟﺜﺎﻟﺜﺔ
  : ﺒﻜل ﻤﺠﻤﻭﻋﺔ ﻜﻤﺎ ﻴﻠﻰ5002/4002ﻭﻜﺎﻥ ﺍﻟﺘﻌﺩﺍﺩ ﺍﻟﻜﻠﻰ ﻟﻠﻤﺭﻀﻰ ﻓﻰ ﺍﻟﻌﺎﻡ 
    ﻤﺭﻴﻀﺎﹰ513ﺍﻟﻤﺠﻤﻭﻋﺔ ﺍﻷﻭﻟﻰ    
   ﻤﺭﻴﻀﺎﹰ9441ﺍﻟﻤﺠﻤﻭﻋﺔ ﺍﻟﺜﺎﻨﻴﺔ   
   ﻤﺭﻴﻀﺎﹰ00092ﺍﻟﻤﺠﻤﻭﻋﺔ ﺍﻟﺜﺎﻟﺜﺔ   
  
ﻭﻤﻥ ﺜﻡ ﺤﺴﺒﺕ ﺍﻟﺘﻜﻠﻔﺔ ﺍﻟﻌﻼﺠﻴﺔ ﺍﻟﻤﺒﺎﺸﺭﺓ ﻭﻏﻴﺭ ﺍﻟﻤﺒﺎﺸﺭﺓ ﻭﺘﻜﻠﻔﺔ ﺍﻟﻐﻴﺎﺏ ﻋﻥ ﺍﻟﻌﻤل 
 ﻤﻠﻴﻭﻥ ﺩﻴﻨﺎﺭ 001ﺤﻴﺙ ﺒﻠﻐﺕ ( ﺘﻜﻠﻔﺔ ﺍﻟﻌﻼﺝ)ﺤﺴﺏ ﻁﺭﻴﻘﺔ ﺍﻟﺼﻴﺩﻟﺔ ﺍﻻﻗﺘﺼﺎﺩﻴﺔ 
. ﻡ5002/4002 ﺇﻟﻰ ﻤﻴﺯﺍﻨﻴﺔ ﺍﻟﺤﻘل ﺍﻟﺼﺤﻰ ﺍﻟﻤﺎﻟﻴﺔ ﻓﻰ ﺍﻟﻌﺎﻡ ﺴﻭﺩﺍﻨﻰ ﻭﺒﻨﺴﺒﺘﻬﺎ
  .ﻤﻥ ﻤﻴﺯﺍﻨﻴﺔ ﺍﻟﺤﻘل ﺍﻟﺼﺤﻰ% 57.12ﻜﻭﻨﺕ ﻨﺴﺒﺔ 
ﻗﺩﺭﺕ ﺘﻜﻠﻔﺔ ﻤﻜﺎﻓﺤﺔ (  ﻤﻠﻴﻭﻥ ﺩﻴﻨﺎﺭ ﺴﻭﺩﺍﻨﻰ561) ﺃﻤﺎ ﻤﻴﺯﺍﻨﻴﺔ ﺼﺤﺔ ﺍﻟﺒﻴﺌﺔ ﺍﻟﺒﺎﻟﻐﺔ 
  .ﻓﻰ ﻨﻔﺱ ﺍﻟﻌﺎﻡ% 7.81ﺍﻟﻤﻼﺭﻴﺎ ﻓﻴﻬﺎ ﺒﺤﻭﺍﻟﻰ 
 
 
 
 
 
 
 
 
 
Abstract 
 
The study, which composed of two parts, was conducted in the period 
2004/2006 in Kenana Sugar Company Project.  The first part intended to 
determine the sensitivity of plasmodium falciparum to chloroquine in the 
daily routine treatment of simple malaria in Kenana health centers. For 
this purpose the first 50 simple malaria outpatients with a confirmed 
positive blood film (BFFM) and a definite parasite count, in four different 
located health centers (HC A2, HC A3, HC A6 and Factory HC), were 
followed up for four weeks while under treatment with chloroquine.  The 
treatment failure rate was found to be 20% - 22%, which indicates a 
sensitivity or response of 78 – 80%  to CQ. 
The malaria prevalence in the area companing with other disease was 
determined and it was found to be 37%, 28% and 15% throw the years 
2004/2005 and 2006 respectively. 
The mortality due to malaria showed a decline rate from 0.97% to 0.14% 
till 0.0% throw the year 2004, 2005 and 2006 respectively.  It is an 
indication of an effort of combating malaria and case management. 
It was found that the positive blood film slides showed low percentages; 
8% in the Clinic, 13% in the hospital and 23% in the factory health 
center.  
The second part was set to determine the economical impact of malaria as 
a socio-economical burden on Kenana Sugar Company.  To achieve this, 
three groups each of 50 patients were considered. 
     Group I:     Malaria in-patient (employees) 
     Group II:     Malaria in-patient (employees sponsors) 
     Group III:   Malaria out-patient (employees plus their sponsors) 
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 The cost of illness as a pharmaco-ecnomic method was applied to 
determine the direct and the indirect costs for each group.   
The total cost of malaria was compared to health annual budget and the 
environmental health component. 
In this study the cost of malaria in 2004/2005 was found to be 100 million 
SD. That was equal to 21,75% of the health services budget, (HSB) and 
1,4% of the total payroll.  The malaria combat swallowed 18.7% of the 
environmental health budget. 
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ANNEXES    
 
 
 1  
Part I 
1. Introduction 
1.1 Kenana Project (area & population) 
 
Kenana sugar company, the biggest sugar factory in Sudan and 
the third biggest one in the world, lies 26 Km south east Rabak in the 
White Nile State, and 300 Km south of Khartoum. 
 The irrigated area is (420 x 106 m2) cultivated with sugar cane, 
about 25% of the irrigation water runs to the drain system, which 
leads to the formation of vast pools, which is a suitable media for 
mosquito breeding. 
 The total population is about 100 000 of whom 6500 constitute 
the permanent manpower of the factory and 6000 are seasonal 
workers.  The ethnic structure of Kenana society is heterogeneous 
from all parts of Sudan. In addition more than 240 expatriate are 
working in Kenana, the majority of them are from Asia, where 
malaria  is an endemic. 
The medical services, which cover all Kenana and the surrounding 
area, consist of: 
a) A 120 bed hospital provided with all necessary staff and 
diagnostic facilities. 
b) Eight health centers located at the cultivated areas (area I to 
area VI), the factory and the township.  All of them are 
directed by a qualified medical assistance and supplied with all 
necessary diagnostic and treatment facilities. 
c) An environmental health department as a preventive section in 
the medical field.  It is directed by a senior health director and 
provided with necessary tools and means of environmental 
health control. 
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The climate is tropical characterized by its three main seasons, 
summer, autumn and winter.  It rains in summer with an 
average rainfall of about 400 mm. 
1.2 MALARIA IN KENANA: 
No doubt that the malaria disease is the most important of all 
tropical diseases causing many deaths and morbidity.  In 
Kenana area around 30000 people are suffering from malaria 
each year, [this about 30% from total population], and 1% 
from the total cases of malaria in Sudan.  (Global Health, Org. 
2006).  Economically, it is a burden disease especially in an 
endemic, under developed and poor country, where the high 
cost of treatment is a burden on the national economy. 
Kenana being a great sugar cane plantation with considerable 
irrigation is a favorable area for prevalence of mosquito 
species.  The control of the mosquito with insecticides and 
early treatment with systematic protocol is most appropriate.  
However prophylactic measures have to be the goal of the 
Medical and Environmental health services in Kenana. 
1.3 Malaria Life cycle: 
The good knowledge of the malaria parasite life cycle helps 
those who are interested in the malaria eradication and also the 
researchers to find ways to combat eradicate or developing 
new drugs. 
 Development cycle of P. Malaria after giemsa stain (Table IX) 
(A) Sexual development (Gamogony) in the stomach of the female 
anophles mosquito. 
Ia  :   Gametocytes were taken with blood meal 
Ib :   Gamets  Ie  :  00cinet 
Ic :   Fertilization  If  :  00cyte 
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Id :  Zygote   Ig :  Sporocyte 
Ih :  mature, explode sporocyte 
Ii :  sporoziotes in saliva glands of the mosquito  
Za :  Anophles taken sporozoeites by blood meal feeding (bite) 
Zb :  Sporozoit (one) 
(B) Preeythrocyte development in liver 
 (3 – 7)  exoerythocyte cycle 
(C) Erythrocyte developing (schizony) in man. 
 8-9 :  Ring state (schizont) 
 10  :  at the wall of the erythrocyte fixed young schizont ẽ 
  maurerscher spots 
 11  :  morulastate ẽ 20  Merozoites 
12 :  Free merozoites to attack new RBC’s 
13 :  Gametocytes 
Typical stages from peripheral blood: 
i) P. Vivax  ii)  P. Malariae 
a) young ring form schizont 
b) multinuclear schizont 
c) end stage of schizogony (I: Morula  ii) gaenselflower) 
d) male gametocyte 
e) female gametocyte (G. Pierkaksi 1976) 
 
The most common anopheles in Kenana is anopheles gambiae, which 
caused 90% of malaria. 
Others global anopheleses are:  arabiensis, menus donitz, melas 
theobald and buramboe white but the most wide spread and important 
are anopheles gambiae s.s and anopheles arabiensis (susannah & 
Julian (1994). 
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The female anopheles mosquito becomes infected when it feeds on 
human blood containing gametocytes “the sexual terms of the malaria 
parasite. 
The development in the mosquito (sporogony) takes from 7 – 20 
days. 
The stage of the sporozoites in the mosquito ends at the saliva gland 
of the mosquito ready to be injected in the human blood when the 
mosquito takes it’s blood meal. 
Within half an hour these injected sperozoites disappear from human 
blood to enter the liver (Exoerythrocytic phase) 
Merozoites developed in the liver tissue in some days and leave then 
to invade red blood cells.  The erythrocytic phase begins where 
further sexual development occurs (in 48 hours) producing schizonts.  
Schizonts repture to produce merozoites into the blood and cause 
fever, it’s periodicity depends on the species of the plasmodium.  In 
P. falciparum also refer to as sub-tertian or malignant tertian, the 
interval between the fever cycles are irregular frequency a new attack 
of fever occur before the old one disappear. The P. vivax and P. ovale 
may persist in liver cells as dominant form “hypnozoites” capable of 
developing into merozoites months or year later.  Thus the first attack 
of clinical malaria may occur long after the patient left the endemic 
area and the disease may relapse after treatment with drugs that kill 
only the erythrocytic stage of the parasite. (Bell 1987 ) 
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Fig. I Mosquito Life Cycle 
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Fig II      Plasmodium Falciprum Life Cycle 
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P. falciparum and P. Malariae have no persistent exoerythrocytic 
phase but recrudescence of fever may result from multiplication in 
the red cells of parasites which have not been eliminated by treatment 
and immune processes.  
Some of the blood merozoites develop into sexual forms known as 
gametocytes, which grow without dividing and can be recognized in 
the blood film as male and female gametocytes ready to be 
transferred by mosquito bite to mosquito stomach completing the 
parasite life cycle. (G. Pierkaksi 1973) 
 
1.4 Peculiarities of P. falciparum Infection  
 
a)  The specially unpleasant and dangerous effects of P. falciparum 
malaria are related to the occurrence of schizogomy in deep 
capillaries. The red cells, which harbor the schizonts, become 
physically changed and tend to adhere to the internal lining of the 
capillaries.  This together with changes in the capillary walls 
themselves has the effect of producing microcirculatory arrest.  This 
aspect of P. falciparum pathogenesis is only significant in people 
with little immunity to the infection.  Microcirculatory arrest in P. 
falciparum manifests itself in different ways according to the organs 
most affected.  See table (I)     (Bell 1987) 
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Table  I: Pathogenesis of Plasmodium falciparum Malaria 
 
Organ most affected Main symptoms Typical misdiagnosis 
Stomach and  
Intestine 
 
CNS 
 
 
 
 
 
kidneys  
 
 
 
Liver 
 
Lung 
Vomiting and 
Diarrhea 
 
Delirium 
Disorientation 
Stupor 
Coma 
Convulsions 
 
Renal failure with 
Or without oligiuria 
Haemoglobinuria 
 
Jaundice & fever 
 
Pulmonary Odeama 
Gastritis  
 
 
Encephalitis 
Meningo-encephalitis 
 
 
 
 
Nephritis 
 
 
 
Hepatitis 
 
Pneumonia or heart 
failure 
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b)   Cerebral Malaria 
This is the most important lethal complication of P. falciparum 
malaria and occurs only in non-immunes, it characterize by 
disturbance of cerebral function.  The first manifestation is 
usually being the disturbance of the consciousness or fits.  
Total neurological signs sometimes occur. If untreated usually 
progress to coma, brain stem failure and death.   
c) The Black water fever: 
It occurs in P. falciparum malaria when severe intravascular 
hemolysis is associated with hemoglobinurea and renal failure. 
(Bell 1987)  
1.5 Malaria endemicity in Kenana 
The suitable environment for the existence of the endemic 
factors, like parasite, vectors and host is the cause of the 
endemic malaria in Kenana. Endemic is defined as having a 
constant measurable incidence both of cases and parasite 
transmission in an area over a succession of years (WHO 
report 2004). 
Catogrization of endemicity is given by WHO (1963) as 
follows: 
Hypo endemic: little immunity is acquired epidemic is to 
occur and the disease liable doesn’t differ materially from that 
in non-immune. 
Meso endemic: malaria is frequent but only seasonal.  
Repeated infections lead to anemia, considerable enlargement 
of spleen, which is in danger with rupture and chronic ill health 
with bouts of fever. 
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Hyper endemic: malaria transmission takes place throughout the 
year but with seasonal increase. Adult develop considerable 
immunity. 
 
Holo endemic: malaria transmission is intense throughout the 
year. 
Davidson’s   (1999). 
 
1.6 Diagnosis of Malaria  
The diagnosis of malaria can be clinically and/or by laboratory 
investigation. 
1.6.1 Clinical diagnosis 
This method which depends on the knowledge and the skill of 
the medical service provider, is not always correct, but in a 
place, where no laboratory facilities it is inevitable.   
1.6.2 Laboratory diagnosis: 
This is either microscopic or/and non-microscopic diagnosis: 
a)  Microscopic diagnosis: depends on the demonstration of 
parasites of the erythrocyte cycle in stained blood film.  Both 
the sexual (gametocytes) and asexual term (trophozites) have 
certain characteristics that enable the identification of malaria 
parasite in any given case. 
In P. falciparum infection it is usual to find only ring form. 
Gametocytes and schizonte are rarely seen.  The infected red 
cells do not increase in size and shiffner’s dots are not 
produced, but with later rings form a few granules, mauer’s 
dots may be demonstrated in infected red cells.  As such large 
number of parasites is produced in P. falciparum infections the 
finding of ten or more ring forms in each oil immersion field 
would strongly indicate such an infection. 
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In Plasmodium malariae infection the ring form assume a 
band appearance, the red cell does not enlarge and rarely 
granules seen.  Mature schizonts have usually eight or ten 
merozoites which seem to be arranged symmetrically. 
In plasmodium vivax infection, the infected red cells increase 
in size and show schiffner’s dots, the cell may reach twice their 
normal size and the parasite have an amoeboid forms. 
In P. ovale infection cells are rather less enlarged and tend to 
destert to an oval shape with drawn and points.  The parasites 
remain rounded and solid.  Schizonts have eight or ten 
merozoites (Chees Brough 1999). 
Stained blood films: are either thick or thin blood films.  The 
stain of the film is concerned with colouring of the nucleus and 
the cytoplasm contents of the parasite.  The thin film is used 
for species confirmation while thick film is useful in the 
detection of parasitaemia, because it has the advantage of 
concentration the parasites by 20-30 fold over the thin film.  
The thick film is dehaemoglobinized and then stained, 
therefore, providing increased sensitively. 
- the field stain, which used only with thick blood film, 
provide rapid diagnosis (stained in less than one minute).  It 
requires proper handling and experience. 
- The giemsa stain is the best, because it can be applied for 
both thin and thick film, is relatively inexpensive and shows 
storage stability and reproducibility of staining quality over 
a wide range of temperature. 
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b)  Non microscopic diagnosis 
       New methods of identification of parasite specific 
molecules have been developed recently.  These methods 
are depending on immunological tests and genetic probes 
i.   Malaria Antigen Test 
ii.  Immunochromatagraphic Test (ICT) 
iii.  Polymerized chain Reaction Test. (PCR) 
i) Malaria antigen Test: 
This test is designed for the differential diagnosis between 
plasmodium falciparum and the other plasmodium species. 
It contains a membrane strip, which is pre-coated with two 
polyclonal antibodies as two separate lines across a test strip.  
One polyclonal antibody (test line I) are specific to the lactate 
dehydrogenase of plasmodium falciparum and the other 
polyclonal antibodies (test line 2) are pan specific to the lactate 
dehydrogenase of plasmodium species.  Conjungated pad is 
disposed with polyclonal antibodies, which is pan specific to 
the lactate dehydrogenase of plasmodium species.  
ii) Immuno Chromatographic Test (ICT) 
The most recent method developed.  It detects the HRP-2-
Antigen which is plasmodium falciparum specific.  It is one 
coloured immunographic assay, which has been designed as an 
in vivo diagnostic test for the detection of P. falciparum in 
whole blood.  The test employs monoclonal antibodies against 
histidinrich protein2 (P.F.HRP2). 
A captured monoclonal antibody is immobilized on a 
nitrocellulose membrane strip. Plasmodium falciparum antigen 
when present in lysed whole blood binds to the antibody as the 
blood migrates along the test strip. Colloidal gold particle also 
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coated with specific monoclonal antibody binds to the P. 
falciparum antigen to form a sandwich with a resulting red line 
(test line) across the test strip, which is visible to the naked 
eye. A second red line (control line ) develops if the test has 
been performed correctly (Zindrou et al  1996).  
iii) Polymerize chain Reaction Test (P.C.R)  
This is highly sensitive and non-radioactive PCR method.  It is used 
for the detection of the four species of plasmodium. Plasmodium 
specific primers corresponding to the small sub unit & RNA 
(Ribosomal-RNA) genes were used and 2G1-bp fragment was 
amplified.  The method was able to detect an early therapeutic 
failure, which can confirm 7 days later by a thick blood film.  
(Ciceron et al 1999) 
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1.7 Malaria Manifestation and Treatment 
Malaria occurs either in a simple uncomplicated or severe and 
complicated form. 
The treatment is differed according to the type of malaria. 
1.7.1 Simple uncomplicated malaria 
The clinical symptoms include always fever, headache fatigue, 
malaise, anorexia and generalized myalgia.  In case of P. 
falicparum malaria the incubation period is from 7-14 days.  
There is a continuous or remittent fever that may be associated 
by rigors, while in some patient the fever is absent 
In P. vivax and P. ovale disease, the incubation period is in the 
range of 13-14 days, but may be 9 month or more with some 
strains of P. vivax. Classical stages of fever are: 
a) Cold phase (15 – 60 minutes) high fever, rigors cold dry 
skin and rapid low volume pulse. 
b) Hot phase (2-6 hours) the body temperature round 41oC 
severe throbbing headache, confusion hallucination and 
rapid full volume pulse. 
c) The sweating phase, which characterized by sweating 
normal temperature and exhausted sleep. P. malariae  
incubation period is (18-40) days it is like P. vivax & ovale 
but differ in occurrence fever fits (every 4 days) (Bell 
1987)  
The treatment of such a simple malaria is supportive & specific 
causal treatment. (Figure III the National Protocol for Malaria 
Treatment 2004) 
a) Supportive treatment: 
- Reducing the temperature if hyperpyrexia is presented.  
This is especially common with P. falciparum malaria. 
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Fig.III General Plan for Malaria Diagnosis and Treatment 
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- Rehydration specially when vomiting and diarrhoea have 
been prominent. 
- Reducing the pain (headache, myalgia) etc. 
- Terminating fits with appropriate anticonvulsant. 
b) Causal treatment: 
The treatment is directed to terminate the parasitaemia as 
rapidly as possible. 
Drugs that prevent the development of the blood stage 
(erythrocytic phase) are called schizontocides.  The mostly 
common used blood schizontocides are:  
- Amodiaquine,  
- Chloroquine  
- Hydroxychloroquine  
- Pyrimethamine  
- Quinine  
- Mefloquine  
- Halofantrine  
- Artemether  
1.7.2 Severe and complicated malaria 
Severe malaria is a life – threatening that is always caused by 
P. falciparum.  The severity of the disease is variable among 
different population and age groups.  The following 
complication have been issued in two editions of WHO 
publication (WHO 1986 and 1990) 
- Cerebral malaria 
- Normocytic anaemia 
- Renal failure 
- Pulmonary oedema 
- Hypoglycemia 
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- Algid malaria 
- Spontaneous bleeding and disseminated intravascular 
coagulation 
- Fluid electrolyte & acid-base disturbance 
- Macroscopic haemoglobinuria 
- Hyperparasitaemia 
- Hyperpyrexia 
- Generalized convulsion 
The higher risk groups are children & non-immune adults in 
endemic area (Gilles 1991 and 1999). 
 The treatment of severe and complicated malaria is also 
directed to cover the supportive treatment and causal treatment, 
which depends on quinine or artemether as a drug of choice. 
(Fig. IV the National Protocol for Malaria Treatment 2004) 
1.8 Classification of Anti-Malarial drugs 
Anti malarial drugs can be classified by their mode of action 
on malaria parasites or by their chemical structure (Gilles 
1999). 
a)  Mode of action: 
* Drugs used for causal prophylaxis: 
They act on primary tissue form of plasmodium within the 
liver, which are destined within less than a month to initiate the 
erythrocytic stage of infection.  Invasion of erythrocytes and 
further transmission of infection are thereby prevented.  The 
prototypic drug for this class is proguanil 
*  Drugs used to prevent relapse: 
They act on latent tissue forms of P. vivax and P.ovale, which 
are remaining after the primary hepatic forms have been 
released into the circulation.Such latent tissue forms eventually 
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Fig. IV  Flow Chart for Diagnosis and Management   
       of Sever Malaria 
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mature, invade the circulation and produce malaria attack i.e. 
relapsing malaria, month or years after the initial infection.  
The prototypic drug is primaquine 
*Drugs used for clinical and suppressive cure: (Blood 
schizontocides) 
They act on asexual erythrocytic stages of malaria parasites to 
interrupt erythrocytic schizogony and thereby terminate clinical 
attack. (Clinical cure).  Such drugs also may produce suppressive 
cure, which refers to complete elimination of parasites from the 
body by continued therapy. 
Inadequate therapy with blood schizontocides may result in 
recrudescence of infection due to erythrocytic schizogony.  These 
agents can be divided into two groups. 
a) Rabidly acting blood schizontocides like chloroquine, quinine 
and their related derivatives quinidine and mefloquine and also 
the endoperoxides, artimisinin and atovagnore. 
b) Slower acting less effective blood schizontocides exemplified 
by the antimalarial antifolate and antibiotic compounds. 
*  Gametocides: 
These agent acts against sexual erythroxytic forms of 
plasmodium, thereby preventing transmission of malaria to 
mosquitoes  
Chloroquine and quinine have gametocidal activity against P. 
vivax, P. ovale and P. malariae whereas primaquine displays 
especially potent activity against gametocytes of P. falciparum.  
However, this group is not used clinically for this purpose. 
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    * Sporonocides:  
Such drugs ablate transmission of malaria by preventing or 
inhibiting formation of malaria ocysts and sporozoites in 
infected mosquitoes. 
Although chloroquine prevents normal plasmodial 
development within the mosquite, it is not used for such 
purpose 
B) Chemical classification: 
The chemical classification of anti-malarial drugs based on the 
chemical structure of the moleule.  The common used 
molecules are: 
- 4-aminoquinolines: chloroquine & amodiquine 
- 8-aminoquinalines: primaquine 
- Arylaminoalcohol: Quinine, Mefloquine Halofantrine 
- Antimetabolites: Pyrimethamine, sulphadoxine and 
proquanil 
- Sesquiterpere endoperoxides: artemisinin artemether, 
artesunate.  
- Antimicrobials: tetracycline, doxycyeline clindamycin and 
azithromycine. (See Figure V) 
1.8.1 Chloroquine: 
 It is a synthetic compound of 4-amino-quinolone; a bitter white 
powder.  As a base it forms salts with acids (avoid drinking acid 
containing drinks during oral therapy with chloroquin). 
The common bases used are: 
Diphosphate  250mg  (150mg base) 
Sulphate  200mg  (150 mg base) 
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It is rapidly and completely absorbed from the gastrointestinal tract, 
reaches the max plasma concentration in about 3 hours and is rapidly 
distributed to the tissue. 
Execration is in urine. T½ equal 3-5 days.  It is highly effective as blood 
schizonticide and also moderate effective against gametocytes of P. 
vivax, P. ovale and P. malariae but not against those of P.falciparum. 
Mechanism of action: 
Several mechanisms have been found by which chloroquine kills the 
organism after accumulating in the vacuoles.  
a)   Damage mediated by accumulated heme: 
Chloroquine probably acts by consentrating in parasite food vacuoles 
preventing the polymerization of the hemoglobin breakdown product, 
heme, into hemozoin and thus eliciting parasite toxicity due to the 
building of free heme (Katzung B. 2000 ). 
Chloroquine also binds to ferroprotenporphyrin ix, which is formed from 
the breakdown of hemoglobin in infected erythrocytes.  The resulting 
complex damages the memberanes and leads to lysis of both the parasite 
and the red blood cell. 
b) Alkalizing of food vacuole: 
 Chloroquine is taken up into the parasite’s food vacuoles by active 
transport system.  Inside the acidic vacuoles,,the drug, which is very basic 
combines with a proton and is trapped, resulting in alkalinization of this 
organelle.  This causes an inability of the parasite to carry on hemoglobin 
digestion. 
c) Decreased DNA synthesis: 
 The drug can also decrease DNA synthesis in the parasite by 
disrupting the tertian structure of the nucleic acid. 
The mechanism of action of chloroquine against blood schizonts remain 
unclear but it may act by influencing haemoglobin digestion by rising 
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intravesicular pH in malaria parasite cell.  It also interferes with synthesis 
of nucleoproteins by the parasite.  (Martindale The extra pharmacopoeias 
(1996 ). 
d) Adverse effects: 
Chloroquine is usually very well tolerated even with prolong use, purities, 
headache various skin eruption, gastrointestinal disturbance, such as 
nausea, vomiting and diarrhea may appear sometimes. 
Visual disturbance such as blurred vision and difficulties in focusing 
occurred but these are more common with prolonged treatment. 
Rapid infusion with CQ can result in severe hypotension, respiratory and 
cardiac arrest. (Martindale The extra Pharmacopoeia  1996 ). 
e) Contraindication: 
Chloroquine is contraindicated when used in-patient with psoriasis or 
porpheria where it may precipitate acute attack of these diseases. 
In patient with retinal or visual abnormalities. 
The antidiarrhoed agent kaolin and calcium and magnesium containing 
antacid interfear with the absorption of chloroquine. 
f) Resistance:   
The mechanism of chloroquine resistance is uncertain and more than one 
mechanism can play a role in different strains.  It’s probably involves 
multiple mechanism under complex multigenic control. (Katzung B. 
1996)) It is accompanied with reduction of chloroquine in the acid food 
vacuole of the parasite due to it’s increased efflux from the cell.  
(chloroquine resistant parasite eliminates the drug 40-50 times more 
rapidly than sensitive parasites. (White 1992).In Plasmodium f. the cause 
of the most lethal human malaria ,chloroquine resistance is linked to 
multiple mutation in PfCRT, a protein that likely functions as a 
transporter in the parasite’s digestive vacoule membrane. Rapid 
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diagnostic assays for PfCRT mutations are already employed as 
surveillance tools for drug resistance. (Wellens, Plowe 2001) 
1.8.2   Amodiaquine: 
 Is closely related to chloroquine and is probably shares the same 
mechanism of action and resistance of chloroquine. 
It is used in so many countries because of it’s low cost, limited toxicity 
and in some areas effectiveness against CRM. 
An important known toxicity of amodiaquine is a granulocytosis. 
 
1.8.3   Quinine and Quinidine: 
 Quinine an alkaloid extracted in 1820 from the bark of cinchona 
tree and from that time it is an a traditional remedy for intermittent fevers 
in south America and as malaria therapy since that time.  Now a days 
quinine remains the drug of choice for treatment of severe and 
complicated malaria. 
 
Anti malaria action and resistance: 
Quinine is rapidly acting highly effective blood schizonticidal against the 
four species of human malaria parasites.  Also it is gametocidal against P. 
vivax, P. ovale but not P. falciparum.  It is not active against liver stages.  
This why it does not produce a radical cure in vivax or ovale malarias 
stage parasites.  The mechanism of action is unclear but it may interfere 
with lysosome function or nucleic and synthesis of the parasite. 
(Martindale the extra pharmacopoeia 1996). 
It can be administered IM. IV and oral but care must be given by IV rate 
controlled infusion.  Base calculation must be taken carefully (10 mg salt 
= 8.3 base).  It is save during pregnancy. 
 24  
It has mild side effects (tinnitus, hearing loss nausea uneasiness, 
restlessness and bluring of vision.  Hypoglycemia is the most serious 
frequent adverse side effect. 
Resistance: 
 In vitro resistance of parasite from different areas suggest that 
quinine resistance will be an increasing problem in the future.  
Contraindication: 
 Contraindicated in-patient with tinnitus or optic neuritis in-patient 
with heart disease in-patient with myasthenia gravis. 
Blood glucose level must be monitored.  A loading dose should not be 
used if the patient has received quinine or mefloquine or halfan during the 
previous 24 hours.  (Martindale the Extra pharmacopoeia ( 1996 )  
1.8.4  Mefloquine: 
 mefloquine is 4-quinolone derivative related to quinine.  It is a 
blood schizontocid effect against cell forms of malaria including 
chloroquine or multidrug – resistance strains of P. falciparum (Martidale 
– the extra pharmacopoeia ( 1996 ). 
It is well a tolerated and the peak plasma concentration reached in 18 
hours is highly protein-bound, widely distributed in tissues and slowly 
eliminated, allowing a single dose treatment regimen.  The terminal 
elimination half-life is about 20 days, this allowed also a weekly 
prophylactic usage. (Katzung B.: 2000 ) 
Anti malaria action: 
 It has strong schizontocidal activity against P.falciparum and P. 
vivax but the mechanism of action is unknown. 
 
 
 
 
 25  
Resistance: 
Resistance to mefloquine has been reported from many areas.  It’s 
resistance appear to be associated with those to quinine and halofantrine 
but not to chloroquine.   (Katzung B. 2000.) 
Adverse effects: 
 Mefloquine is generally well tolerated although some effects like: 
nausea, vomiting dizziness, sleep and behavioral disturbances, epigastric 
pain, abdominal pain, headache neuropsychiatrial toxicity have been 
reported.  (Katzung B. 2000) 
Contraindication: 
 Mefloquine is contra-indicated in patient with epilepsy, psychiatric 
disorder, arrhythmia cardiac condition defect.  (Katzung B. 2000) 
1.8.5  Primaquine: 
 The drug of choice to eradicate exoerythrocytic stage.  Especially 
P. vivax and P. ovale.  For P. falciparum it is a gametocydal but has no 
effect on erythrocytic stages. 
It is a synthetic 8- aminoquinolone orally well absorbed and reaches the 
peak plasma level in 1-2 hours.  T½ is 3-8 hours widely distributed in the 
tissues.  Rapidly metabolized and excreted in the urine. 
The mechanism of action is unknown, but intermediates are believed to 
act as oxidants that are responsible for the schizontocidal effect. 
Adverse effect: 
 It is generally well tolerated in therapeutic dose.  Some effects like, 
nausea, epigastric pain abdominal cramps, headache are sometimes 
common. 
More serious effects but rare are leucopenia agranulocytosis, 
leucocytosis, cardiac arrhythmias and sometimes hemolysis (cyanosis) 
specially in person with G6 PD deficiency. Therefore patient should be 
tested for G6 PD deficiency before primaquine prescription. 
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1.8.6    Halofantrine: 
 a phenanthrene methanol related to quinine is effective against 
erythrocytic stage of all plasmodium species.  It is not active against 
hepatic stages or gametocytes. 
It is taken orally and the absorption is accelerated with food. . plasma 
level peak reached in 16 hours.   
The T½ is 4 days.  Excretion is mainly in feces.  The mechanism of 
action is still unknown.  (Katzung B. 2000) 
Adverse effect: 
 Halofantrine is generally well tolerated, the most common adverse 
effect are, abdominal pain, diarrhea, vomiting, cough, rash, headache 
pruritis and elevated liver enzymes of greater concern the drug after 
cardiac conduction ,with dose-related prolongation of   QT and PR 
intervals. 
Contra indication: 
 In patient with cardiac condition defects. And should not be used 
during pregnancy.  (Katzung B. 2000) 
 
1.8.7    Artemisinin and derivatives: 
 Artemisinin (Qinghaosu) is a sesquiterpene lacton endoperoxide.  
The active principle of this herpal medicine has been used as antipyretic 
in china for over 2000 years.  It is insoluble and therefore can only be 
used orally. 
Analogs have been synthesized to increase the solubility and improve anti 
malarial efficacy. 
Two other important analogs under study are arteether and artecinic acid 
Artesinin and it’s analog (artesunate) are rapidly absorbed with plasma 
level of 1-2 hours and T½  of 1-3 hours, after oral adminstration.  The 
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compounds are rapidly metabolized to the active  metabolite 
dihydroartemisin. 
They act as blood schizontocide against all human plasmodium species 
and have no effect on hepatic stages. 
Mechanism of action: 
The antimalarial activity of artemisine and derivatives result from the 
production of free radicals that follows the iron catalyzed cleavage of the 
artmisinin endoperoxide bridge in the parasite food vacuoles. 
It is used to treat multidrug resistance P.falciparum malaria.  They are the 
only drugs reliably effective against quinine – resistance strains. 
The efficacy of the artemisinins is limited some what by their short 
plasma half lives (T½)1-3 hours 
Recrundescence rates are unacceptably high after short course or 7 days 
of therapy, and these drugs are best used in conjunction with another 
agent such as doxycycline or fansidar for this short T½  the drug is not 
recommended for proplylaxis. 
Adverse effect: 
 Artmisin seems to be better tolerated than most anti malarial.  The 
most commonly reported adverse effect is nausea and vomiting.  Not 
recommended during pregnancy. 
1.8.8        Tetracycline: 
 a number of antibiotics in addition to the folate antagonist and 
sulphonamides have anti-malarial activity. 
The mode of action is not clear.  They may inhibit protein synthesis or 
other functions in two plasmodia prokaryote – like organielles, the 
mitochondrion and the newly described plastid.  This action is much 
slower than the classic anti-malarial, therefore they are used in 
combination with anti-malarial agents.  
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Tetracycline and doxycycline are active against erythrocytic schizonts of 
all human malaria parasite.. Clindamyin in case of contraindication of 
tetra and doxycycline is used.  It is slowly active against erythrocytic 
schizonts.  (Katzung B. 2000). 
 
1.8.9  Anti-Malarial Drug Combination: 
 a)  Sulphadoxine 500mg + Pyrimethamine 25mg (Fansidar)  
 Those known as folate antagonist inhibitor of folate 
synthese.  Where pyrimethamine selectively inhibit plasmodial 
dihydrofolate reductase (a key enzyme in the pathway for synthesis 
of folate.  Sulphonamide (sulphadoxime, and sulfurs) inhibit 
another enzyme in the folate pathway, dihydroplerate synthase.  
This combination of these two enzyme inhibitors provides 
synergistic activity in favour of their therapeutic strength.  
(Katzung B. 2000) 
 b) Coartem: 
A new combination of artemether 20mg and lumefantnine 
120mg.  As it recommended by the M. of H as a second line 
treatment three days course of 6 days regimen.  Also as oral 
treatment. 
 
 c)  Artesunate – Sulphadoxine/Pyrimethamine (500/25)  
A combination of artesunate 100mg + sulphadoxin/ 
pyrimethamine (500/25).  Recommended by the Ministry of Health 
as a first line malaria treatment for adult and 50mg artesunates + 
sulphadoxine/pyrimethamine (500/25) for children  It is an oral 
therapy. 
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1.9 Drug Resistance: 
 Antimalarial drug resistance is the ability of aparasite strain to 
survive and/or multiple despite the administration and obsorption of a 
drug given in doses equal to or higher than those usually recommended 
but within the limits of tolerance of the subject. (WHO 1997).  In the case 
of anti-malarial drugs, the spread of strains of plasmodian falciparum 
resistance to chloroquine and other anti-malarial drugs is still causing 
great concern. Several mechanism can account for changes in drug 
sensitivity in the malaria parasites, for example:  physiological adaptation 
due to non genetic changes, selection of previously existing drug 
resistance cells from a mixed population under drug pressure, 
spontaneous mutation, mutation of extranuclear genes, or the existence of 
plasmid like factor.   
1.9.1  Classification of Resistant  
 Chloroquine resistance is classified into 3 types according to the 
response of the parasite to normal full doses of chloroqine in a patient 
who is non immune (Bell 1987) 
RI :   is defined as clearance of a sexual parasitaemia and good condition 
of the patient  followed by recrudescence within 7 to 10 days. 
RII: is defined as marked reduction of parasitaemia but no clearance. 
Symptoms return the day of stopping the treatment. 
RIII: is defined as no marked reduction in parasitaemia and no 
improvement in spite of taken anti malarial.  
 Wherever chloroquine resistance occurs RIII resistance patterns is 
usually less common than RI or RII patterns.  It is obviously 
impossible to detect the earliest stages of chloroquine resistance in 
the immune indigenous population (Bell 1987) 
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1.9.2  Spread of resistance 
The increased number of fatalities due to severe and complicated 
malaria is mainly attributed to the treatment failure associated with 
the widespread resistance to chloroquine and other antimalarial.  
The following aspect may share in malaria resistance spreading. 
-  Uncontrolled movement of malaria carrier 
-  Irrational prescribing or self medication. 
-  Incomplete malaria treatment 
- lack of knowledge about etiology & epidemiology of malaria 
Chloroquine resistance was first documented in 1961.  proguanin, 
pyrimethamine and mepacrin in 1963.  Quinine plus tetracycline in 
1974, mefloquine and pyrimethamine/sulphadoxine in 1985 (Dutta 
1995 WHO 1995). 
During the early 1980’s chloroquine was no longer recommended 
for the treatment of P.falciparum malaria in many parts of south-
east Asia and South America.  At present multi-drug resistance has 
been confirmed in many malaria endemic areas. 
Chloroquine-resistance P. falciparum is wide-spread across Africa 
and resistance to pyrimethamine/sulphadoxine is increasing (Ronn 
et al 1996). (See Figure VI) 
1.9.3  Mechanism of Drug Resistance 
The mechanism of resistance to chloroquine is accompanied with 
it’s reduced concentration in the acid food vacuole of the parasite 
due to it’s increased efflux from the cell.  Chloroquine resistance 
parasites eliminate the drug 40-50 times more rapidly than 
sensitive parasites.  This expulsion process is energy dependent 
that can be inhibited by ATP blockade, calcium-channel blockers, 
tricycle antidepressants, phenothiazines and cyproheptadine to 
reverse the drug resistance (White 1992). 
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It has been demonstrated that P.falciparum contains two                
P-glycoprotein homologues Pgh-I and Pgh-2 that are encoded by 
two separate genes Pfmdr-1 Pfmdr2.  Pgh-1 is located in the 
surface of the acid vesicle and appear to be directly or indirectly 
involved in concentrating chloroquine into this organelle.  The 
gene Pfmdr-1 amplification has been observed in some parasites 
that are resistance to chloroquine, and mutation within this gene 
have been revealed to be correlated with the resistance phenotype 
(Simon and Alan 1994) 
Sulphonamide inhibit dihydropteroate synthetase, while 
pyrimethamine inhibit the bifunctional enzyme dihydrofolate 
reductase (DHFR)/thymidilate synthase thus interfearing 
senergistically with folic acid synthesis in the parasite. 
Proquanil and pyrimethamine resistance to P.falciparum results 
from reduced affinity of the (DHFR)/thymidilate synthase enzyme 
complex for the drugs, which has been attributed to several distinct 
single base-pair mutations leading to affinities 100-1000 times less 
than that of the drug-sensitive DHFR complex (White 1992 Simon 
and Alan 1994). 
The resistance to other quinoline-containing antmalarial is less well 
defined. The amplification and over expression of the Pfmdr-1 
gene has been demonstrated in all mefloquine resistance parasites. 
Across-resistance between mefloquine and halofantrine has been 
confirmed in field isolates (Wilson et al 1993).   
The correlation between mefloquine and quinine resistance has 
been established by in vivo and in vitro studies.  The amplification 
of Pfmdr-1 gene in the mefloquine resistance parasites might be 
attributed to inappropriate quinine regimens.  (Brasseur et al 1991). 
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1.10   Malaria Control: 
Great efforts have been given to reduce malaria transmission in 
Sudan.  For this purpose the Sudanese National Malarial 
Directorate has been established.  
WHO was adopted a global malaria control, where prevention of 
death, reduction of illness and decrease of social and economical 
loss due to malaria, were the main goal. (WHO 1993) 
The four basic technical elemonate of WHO’s global malaria 
control strategy have been summarized as: 
1- Provision of early diagnosis and prompt treatment of the disease 
2- Planning and implementation of selective and sustainable 
preventive measures including vector control. 
3- Early detection for the prevention of epidemics 
4- Strengthening of local research capacities to prompt regular 
assessment of a country’s malaria situation in particular the 
ecological, social and economic determinants of the disease. 
Other control measurements can be provided: 
a) Measures provide protection against infection by (impregnated 
bed nets mosquito repellents…etc) 
b) Measures provide community protection using of insecticides 
in large scale. 
c) Measures provide prophylaxis using drug as prophylactic for 
non immure persons. 
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1 . 11   Immunity in malaria: 
Malaria in  kenana is an endemic disease, 30 % of the population suffer 
from malaria yearly), however, there  is  a considerable  number  of  
kenana  citizen  who don’t  have  malaria  attack during  their stay  in  
kenana.   This could be due to an acquired immunity against malaria.  
The Immunity has two main components: 
1)  An ability  to  limit parasitaemia  by  the  development of  
specific  protective  IgG   and  CMI   . 
2) Physiological tolerance   such that low parasitaemia produces no 
fever or subjective illness. In order to maintain this immunity 
frequent re-exposure to infection is required. If this dose not occur 
the immunity wanes over a period of few years. Therefore, the 
impregnated mosquito nets should not be used for such individuals. 
This naturally acquired immunity might be suppressed during 
pregnancy, major surgery, or severe illness or any type of immune   
suppressive drugs.  (Bell 1987)               
1 : 12  Malaria vaccine : 
Many efforts have been given to control malaria in the world especially in 
Africa, but these have met with only limited success. 
Vectors control, chemoprophylaxis and chemotherapy programs have all 
achieved some success, but the appearance of both insecticide and drug 
resistance has taken away many of these gains, so that the malaria remain 
still a serious health problem in many parts of the world. 
Considering this context the development of an effective malaria vaccine 
would represent an important step in malaria control. 
Malaria parasite is an intracellular pathogen, for which an effective 
vaccine is likely to require induction of cell – mediated immunity. 
Many researchers are seeking immunization approaches that stimulate 
strong and persistent levels of effectors T-cells. 
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DNA vaccines recombinant protein and viral vectors were amongst 
vaccine delivery systems that appeared promising for the generation of 
cellular immunity.  In some initial studies in small animals this goal was 
achieved, however, clinical trails of these candidate vaccine when used 
alone or in repeated homologous boosting regimes have been 
disappointed with short lived low levels of induced T-cell responses. 
Recent years have seen the development of immunization strategies using 
a combination of different antigen delivery system encoding the same 
epitopes or antigen, delivered at an interval of a few weeks apart.  This 
sequential immunization approach with different vectors is known as 
heterologous prim-boosting and is capable of inducing greatly enhanced 
and persistent levels of CD-8 + T cells and ThI – type CD4 + T cells 
compared to homologous boosting. 
The prim boost approach represents an encouraging step towards 
establishing and effective preventative vaccine to one of the world’s 
greatest killer.  (Donachie and. Hill 2006). 
Since 1999 a series of heterologous prime boost vaccine trials have been 
underway in Oxford to assess the safety immunogenicity and efficacy 
against sporozoite challenge of several combination of vectors in healthy 
malaria naïve volunteers.  The initial vaccine candidate used were DNA 
and MVA (modified vaccinia virus Ankara) constructs encoding a 
multiple epitope (ME) string and the entire PfTg/96 strain TRAP antigen.  
The polyepitope string includes 14 CD8 + T cell epitopes from six 
preenythrocytic P. falciparum antigen and six further B-cell or T-cell 
epitopes.  The DNA vaccine was delivered at dose of up to 2mg by intra-
muscular injection or 4 µg by intra epidermal injection at dose up to 15 x 
107 P.f.u (plaque forming units)  An excellent safety profile for the 
vaccines alone or sequentially has been in over 150 subjects in total 
(Moorthy et al 2003). 
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Sporozoites have been shown to induce immune protection both in 
experimental models and following natural malaria infection.  Antibodies 
produced against sporozites recognize a main protein located on the 
external coal, the circumsporozoite (Cs) protein, which contain number of 
amino-acids (4-12) tenderly repeated (10-37) times.  Such repetitive 
epitopes, which appear to be the target of antibody recognition, have been 
produced both by chemical synthesis and by recombinant DNA 
technology and are being tested as potential malaria vaccine. (American 
Journal., Tropical med and hygyne 3612 – 1983) 
Cox and co-workers have reported that the immunity (as a result of 
injection of purified protein of irradiated merozoites and schizonts), may 
result from antibodies to the malaria parasite aldolase. Aldolase catalyses 
the reaction of fructose – 1,6 diphosphate to glyceraldehyde – 3 
phosphate and dihydroxy acetone phosphate. 
The importance of this enzyme (Aldolase), is that the blood stages of the 
malaria parasite lack citric acid cycle and so uses a vast amount of 
glucose.  This inhibition of the aldolase would therefore inhibit the 
maturation of the parasite and subsequent invasion of new blood cells.   
Therefore aldolase could be a base for vaccine against many if not all 
types of malaria (Cox 1988). In vaccine research, genetic engineering is 
used to characterize antigens.  The first genetically engineered vaccines to 
be tested in malaria already exist, but many obstacles remain to be 
overcome. (Ryser and Weber –1992). As the genetic engineering is 
progressing, a real effective vaccine for malaria is not impossible, if the 
following prerequisitions of the vaccine are achieved: 
- long duration of effectiveness, 
- affordable price (poor countries), 
- minimum side effects, 
- covering all species of plasmodium, 
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Part II – Economical Impact of malaria in KSC 
 
1.1 Introduction 
 
Malaria represents worldwide socio-economic problem e.g. in sub-
Sahara Africa the WHO estimation of direct and indirect cost of 
malaria were:  US$ 0.8, 1.8 and more than 2 Billion in the years 
1984, 1995 and 1997 respectively, (WHO 1998).  
In India malaria is responsible for economic loss between US $0.5 
to 1.0 billion annually. (Sharma PV. Malaria cost to India and 
future trend.  Southeast Asian J. Trop. Med. Public Health 1996 
Mar; 27(4-14). 
Globally the interest in rolling back malaria is increased and so 
many governmental and non governmental organization are 
participating in this project e.g Bill and Melinda gates foundation 
(USA) is committed $US 83.5 million in new grants to combat the 
disease, which claims more than one million lives every year.  
(Major Commitment to Global fights against Malaria. 
http://www.Sudan.net/news/press/postedr/356shtm! (2007) 
The Islamic development Bank agrees to finance malaria roll back 
program in Sudan with a loan of 7.72 million US$ in addition to a 
donation of further two million US$    (Malaria roll back program) 
 As malaria presents the highest prevalence rate among other 
diseases in Kenana, which affect directly the health service budget, 
this pharmaco-economics study is therefore to highlight the 
economical effect of malaria in this very important sugar factory in 
the Sudan, where the whole health services (environmental and 
medical) is the burden of Kenana Sugar Company.   
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1.2 Place of the Study: 
 
The study is carried out in Kenana hospital. The hospital capacity 
is 120 beds with complete medical staff. The hospital provides it’s 
services to more than 6500 permanent employees with their 
families and 6000 seasonal workers.  Emergency cases from the 
surrounding area are also considered by the hospital. 
Simple malaria cases are managed as outpatients by general 
practitioners and medical assistants at the hospital clinic as well as 
in the health centers located at the project agricultural areas (A1 to 
A6) by medical assistant, where severe malaria patients are 
managed as in patient in the hospital. 
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2.  Aim and Objectives of the Study: 
For this hospital and health centers based study at Kenana Sugar 
Company area where malaria is the most prevalent disease, was 
carried out to: 
a) Determine the prevalence, endemicity, treatment and control of 
malaria. 
b) Estimate the sensitivity rate of Plasmodium falciparum malaria 
to chloroquine.  
c) Determine the economical impact of the disease upon the 
company where the free health services (curative and 
preventive) is the concern of the company. 
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Part I :  Sensitivity of P.f malaria to CQ 
2.1 Materials and methods 
2.2 Materials: 
a) Laboratory material 
Giemsa stain: 
- Giemsa powder: (3-8g) Giemsa Azur-Eosin Methylenblane Art No 
9203 – Merck – Germany. 
- Methanol: (250ml) Fluka Chemika – Switzerland Art No 65543  
- Glycerol: Pure glycerin  - Medical Technology Company . Sudan. 
- Buffer solution: Na2 HPO4 K2HPO4  
- Slides – Mico Brand: Mico glass industries Delhi India. 
- Blood Lancet: Heinz Herenz GMBH. Germany 
All chemicals and reagent required for staining of blood films were 
analytical pure grade and were supplied from Kenana hospital 
laboratory. 
b)  Anti-malaria  drugs;-                                             Exp. Date            
-  Chloroquine Amp.  BN;15188  L.R France         2009 
-  Chloroquine tab.  BN; 030634 Shiffa Sud.        2006 
-  Chloroquine syr  BN; 88 EI Bells England   2006 
All those drugs batches were certified to assure and confirm the 
exact ingredient content of each batch so as to exclude the under 
dosed if any.  Certification was conducted by: 
- The Sudanese national laboratory in Khartoum 
- Jordan pharmaceutical manufacture in Amman – Jordan 
- Those used in the surrounding area but not for this study were 
analyzed by: 
- Jordan pharmaceutical manufacture in Amman – Jordan 
- Middle east pharmaceutical manufacture in Amman – Jordan.    
(Annex No 1)                                                
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2.3 Methods: 
2.3.1: Patient selection:   
This is directed to the B.F positive simple malaria patients, who 
were randomly selected during the routine malaria treatment with 
chloroquine. 
2.3.2: Location: 
The study was carried out at Kenana Sugar Company health 
Centers in different areas (Area II, III, VI and factory health 
center). See  ( Figure VII). 
2.3.3: Sampling and sample size: 
The first 50 B.F positive simple malaria patients were randomly 
selected during the routine malaria treatment with CQ and followed 
up.  
2.3.4:  Duration: 
Sample were taken from patients having malaria during 2004/2005. 
2.3.5:  Follow-up: 
The WHO follow-up criteria was implemented (from the first day 
(Do) to the last day (D28)  (WHO  2000) 
f) On Do:  confirmed positive simple malaria with know 
parasite count, was treated by CQ (oral or injectable) and 
patient is asked to come on D3. 
g) On D3: Clinical assessment was done, if clinical or 
parasitological symptoms developed, this was considered as 
early treatment failure (ETF).  In case of adequate clinical 
response (ACR), patients were asked to come on D7. 
h) On D7: Clinical assessment was done, if clinical or 
parasitological symptoms developed. It was a late treatment 
failure (LTF), otherwise the patient was asked to come on 
D14. 
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i) On D14:  The assessment either (LTF) or (ACR).  In case of 
ACR the confirmation would be on D28. 
Special form is designed for this purpose (Annex  No.II )    
2.3.6: The parasite Count Method:  
 The method used is the plus system: 
 +   1-10 parasite per 100 field 
 ++   11-100 parasite per 100 field 
 +++   1-10 parasite per one field 
 ++++   11to100 parasite per one field   
2.3.7: Determination of CRM%: 
 The resistance percentage is calculated as follows: 
 CRM%  =  Number of resistance cases x 100 
    50 patients 
2.3.8 prevalence & mortality rate: 
Prevalence is the proportion of the population that is affected by a 
disease at a given point in time (WHO 1994) information system 
for the evaluation of malaria control program – a practical guide. 
The prevalence of malaria at the health centers is determined 
following the daily registration of the malaria patient in the area 
health centers and the monthly report. 
The mortality rate or case failure rate (CFR): it is the incidence rate 
of death (for malaria it is the number of deaths due to malaria as a 
percentage from the total number of malaria cases in a given unit of 
time .It is an indication of malaria control and case management. It 
was determine from the malaria in-patients monthly report. (See 
table III, IV, V) 
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Fig. VII   Allocation of Health Centres at the Irrigated Areas     
         ( A1 to A6 of Kenana Sugar Company) 
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Part II – Economical impact of malaria in KSC 
 
2.1 Method of Study: 
2.1.1:  patient selection: 
 The study which was conducted in Kenana Sugar Company 
Hospital consist of three groups of patients: 
 Group I:  Admitted malaria patients (employees) 
 Group II:  Admitted malaria patients (employees families) 
 Group III: Out-patient (employees and families) 
2.1.2:  Location: 
The study was carried out at Kenana Sugar Company out- side 
clinic and hospital wards. 
2.1.3: Sampling and sample size: 
50 malaria patients were randomly selected from each group during 
their routine treatment in the hospital to a total number of : 
Group I: 315 
Group II: 1449 
Group III: 29000 
2.1.4:  Duration: 
Sample was taken from malaria patients having treatment during 
2004/2005. 
2.1.5: Perspective: 
 It is a hospital-based perspective study. 
2.1.6:  Pharmaco- economic method: 
This is an economical method which based on economics as the 
study of the process of man’s attempts to satisfy his material wants 
for goods and services.   Pharmaco economic is therefore to 
determine the alternatives that provide the best health care outcome 
per unit of money (dollars, SDG…etc.) 
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Pharmaco economic research uses various analytical methods to 
identify, measure and compare costs and consequences of 
therapeutics alternatives.  The cost of illness is a pharmaco 
economic method, which concerns with the determination of the 
consumed resources like: 
- Medical resources 
- Non-medical resources, associated with it 
- Lost of productivity 
- Intangible cost 
all those resources have a cost category, which can be: 
- Direct cost 
- Indirect cost 
- Intangible cost  
(Izham.M. (2005) not published lecture notes 
2.1.7:  Statistical method of analysis. 
 The statistical method used is descriptive statistic. 
2.1.8:  Cost categories: 
 Direct and indirect cost: 
a)  Direct cost:   This cost affects directly the hospital and it       
includes: 
i) Cost of medicine used to treat malaria and medical 
consumables as adjuncts. (Annex 10) 
ii)   Cost of laboratory investigations and other diagnostic means 
like (U/S, x-ray…etc.) (Annex 10) 
iii) Hospital cost (administration, nursing, food and 
accommodation) (Annex 10) 
b) Indirect cost:  This is the cost, which affect directly the 
company, it includes. 
*  Bed rest days cost (the admission days for each patient). 
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* Absenteeism days cost (the admitted days plus excused duty service 
(EDS) days after patient discharge) 
* Opportunity cost (the working hours lost) 
* Environmental health cost the budget, which allocated for prevention of 
malaria. (Annex 11) 
d) Total cost:  this is the sum of all above mentioned costs from 
which the following cost is calculated: 
i) % of malaria cost regarding the  health service budget ( HSB) 
ii) % of each group regarding the HSB) 
iii) Absenteeism cost regarding payroll. (Izham M. (2005) 
2.1.9 Calculation of the cost: 
The cost of each group (I, II and III) were calculated as follows: 
Group I:  (Inpatient employees) 
a) the daily income of each admitted employee was determined. 
b) The days which spent in the hospital as in-patient (hospital 
days) were registered. 
c) The days given from the hospital after discharge (EDS) were 
registered. 
d) The absenteeism days are the sum of hospital days plus (EDS) 
days. 
e) Absenteeism cost is the multiplication of the income per day 
and the absenteeism days: (inc/day x Abs. Days). 
f) Opportunity cost;  this is the lost working hours which equal to 
the income per day multiplied by absenteeism days (as 
minimum cost) 
g) The hospital cost per each patient per day is calculated from the 
health services budget (hospital) per day (hospital running cost) 
and multiplied by the hospital days 
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h) Treatment cost:  this is the cost of medicines, medical 
consumable, laboratory and diagnostic means for each 
individual in-patient during the hospital admission (See table II) 
Group II:  Inpatient employees families: 
This group has no direct economical effect upon the company but 
they directly affect the health service budget, hence they are 
entitled to free medication. 
The cost of this group was calculated as follows: 
a) The hospital cost is the hospital cost per day multiplied by 
hospital days of each inpatient. 
b) Treatment cost: is the cost of medicines, medical supplies, 
laboratory and diagnostic means used during hospital days. 
Group III:  Outpatient: 
This is the group of employees and their families.  As they usually 
suffer from simple malaria and not required hospital admittance, 
their cost is limited to: 
a) Administration cost:  this consists of staff cost (cardex clerk, 
statistic clerk, medical assistance, assistant Pharmacist Drug 
register, medical card and constant laboratory cost. 
b)Treatment Cost : Cost of medicine  used for simple  malaria.  
The absenteeism of the employees due to the simple malaria is 
neglected because of the short stay in the clinic. 
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Part I:  The Sensitivity of Plasmodium F. to chloroquine: 
3.1 Sensitivity of Plasmodium f. to chloroquine: 
According to the survey conducted in Kenana health centers, the 
sensitivity of plasmodium f. to CQ showed a relative similar rate 
ranged between 78% - 82%, where the resistance was found to be 18 
– 22%.  As can be seen most of the resistance type was late type and 
few early type.  (Table II) 
3.2 Malaria prevalence: 
The percentage of the malaria frequency was 37%, 28% and 15% in 
the years 2004, 2005 and 2006 respectively. (Table I, II and III) 
The malaria prevalence picture showed a high slide positive rate 
(HSPR) and low slide positive rate (LSPR) according to the climate 
and following the flux of work demanders.   This rate is coinciding 
with the malaria in-patient frequency (Table IV to VI) 
The prevalence of malaria in Kenana health centers follow the 
population density, where the high prevalence rate is in the township 
(clinic and health centers)  (Table VI). 
According to this study and malaria endemicity definition Kenana is 
endemic. 
3.3 Malaria mortality rate: 
The mortality rate was found to be 0.9% , 0.14% and 0.00% in the years 
2004, 2005 and 2006 respectively.     (Table  I, II and III).  
Antimalaria drug used: 
In this study only Chloroquine in oral and inject able form was used 
unless malaria was accompanied with other complains.  The chloroquine 
used batches where certified by Sudanese National Laboratory and 
Pharma International Company Jordan See Annex  (1) 
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Table (II):  Cure Rate & CRM % in KSC selected Health Centers 
 
*Location No of patient *CC No *T.F No *RI *RII *RIII *CC% *CRM% *Pop. 
H. C. A2 50 40 10 2 - 8 80 20 6000 
H. C. A3 50 41 9 - - 9 82 18 4500 
H. C A6 50 39 11 3 - 8 78 22 3100 
H. C Factory 50 40 10 2 - 8 80 20 2276 
Total 200 160 40    80% 20%  
 
*RI   =   resistant categ.   I  *H.C.A2 Health Center area II 
*RII  =  resistant categ. II  *H.C.A3 Health Center area III 
*RIII  = resistant categ.  III  *H.C.A6 Health Center area VI 
       *H.C.Fact. Health Center factory 
*CC No =  Complete cure *  T.F No = Total failure     *  CRM = Chloroquine resistant  
* Pop.  =  Number of  population in each health center 
 51  
 
 
Tabel (II1) 
 Malaria prevalence & Mortality Rate in Kenana Hospital (  2004) 
 
Month 
Total   
Freq. 
Malaria 
Freq. 
 
% 
Total in 
Patient 
Malaria in 
Patient 
 
% 
Total 
Mortality 
Malaria 
Mortality 
 
% 
Jan. 10372 3737 36.03% 563 39 6.93% 3 1  
Feb. 8656 3021 34.90% 444 48 10.31% 2 -  
March 4942 2440 49.38% 257 61 23.74% 2 1  
April 6288 2540 40.4% 283 53 18.73% - -  
May 11649 2582 22.17% 232 55 23.71% - -  
June 7840 2699 32.43% 532 53 9.97% 2 2  
July 6616 3157 47.72% 562 94 16.73% 1 1  
August 7306 2718 37.18% 702 105 14.96% 1 1  
Sept. 9037 3368 37.27% 766 130 16.985% 1 1  
Oct. 8949 3760 42.02% 609 125 20.53% 1 1  
Nov. 7376 3033 41.12% 685 188 27.45% 3 2  
Dec. 7887 2968 37.64% 560 180 26.79% 1 1  
Total 96918 36023 37.17% 6195 1113 18.26% 17 11 0.97% 
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Tabel (IV) 
Malaria prevalence& Mortality Rate in Kenana Hospital (  2005) 
 
 
Month 
Total  
Feq. 
Malaria 
Freq. 
 
% 
Total in 
Patient 
Malaria in 
Patient 
 
% 
Total 
Mortality 
Malaria 
Mortality 
 
% 
Jan. 7689 2261  425 128  1 -  
Feb. 6639 2292  481 129  2 2  
March 6522 2031  436 137  - -  
April 7308 1597  412 128  - -  
May 7754 2627  410 129  - -  
June 6914 1559  507 134  - -  
July 7958 1818  609 93  1 -  
August 9245 2354  677 120  - -  
Sept. 9426 2035  809 109  - -  
Oct. 7316 2531  841 127  - -  
Nov. 8759 2868  845 114  1 -  
Dec. 8457 2323  756 97  - -  
Total 93987 26296 28% 7208 1445 20% 5 2 0.14% 
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Table (V) 
Malaria prevalence& Mortality Rate in Kenana Hospital  2006 
 
Month 
Total f 
Freq. 
Malaria 
Freq. 
 
% 
Total in 
Patient 
Malaria in 
Patient 
 
% 
Total 
Mortality 
Malaria 
Mortality 
 
% 
Jan. 10879 2054 19 % 404 133  1 -  
Feb. 9729 1337 14 % 422 106  1 -  
March 9741 1752 18 % 439 133  1 -  
April 9518 1337 15 % 548 126  1 -  
May 9596 1216 13 % 598 117   -  
June 9715 1180 12 % 617 121   -  
July 10252 1261 12 % 458 129   -  
August 11075 1338 12 % 592 114  3 -  
Sept. 12539 2151 17 % 758 276  1 -  
Oct. 11821 1937 16 % 621 315  4 -  
Nov. 12292 2047 17% 852 346   -  
Dec. 11521 1554 13% 914 263   -  
Total 128678 38527 15% 7223 2179 30.20% 12 - 0.0% 
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Table (VI) 
Malaria Prevalence in Kenana Health Centers  (2004/2005) 
 
Month A1 A2 A3 A4 A5 A6 Clinic Factory P.S4 Total 
08/04 340 150 337 295 201 180 803 419 243 2,968 
09/4 198 250 346 247 254 238 851 393 256 3,033 
10/4 281 240 348 336 337 476 1061 320 325 3,724 
11/04 228 180 368 231 276 410 1010 382 283 3,368 
12/04 166 130 325 180 274 342 806 238 257 2,718 
01/05 223 110 357 168 143 121 540 360 194 2,216 
02/05 223 165 347 150 191 93 585 366 172 2,292 
03/05 157 150 342 110 152 95 600 347 78 2,031 
04/05 122 104 347 78 149 136 281 237 143 1,597 
05/05 130 80 363 85 88 130 560 48 143 1,627 
06/05 160 120 327 89 177 113 348 54 171 1,559 
07/05 144 119 200 130 225 125 595 87 193 1,818 
           
Total 2,372 1,798 4,007 2,099 2,467 2,459 8,040 3,251 2,458 28,951 
Percentage 8.2 6.2 13.8 7.3 8.5 8.5 27.8 11.2 8.5 100.0 
Average 198 150 334 175 206 205 670 271 205 2,413 
STD 65 52 44 88 70 132 241 137 70 737 
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Figure VIII 
Percentage Prevalence of Malaria in different KSC Areas
2004/2005
6%
14%
7%
9%
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Table  VII 
Malaria Blood Film Positive Rates 2004/2005 
A- KSC - Hospital Lab 
 
 
Month Nov. Dec. Jan. Feb. March April May June July August Sept. Oct. Total 
 
Diagnosis 2004 2004 2005 2005 2005 2005 2005 2005 2005 2005 2005 2005   
                             
 
BFFM 920 885 813 703 807 719 618 770 900 1101 1146 1025 10407 
 
               
 
 +ve 211 195 181 75 77 50 35 37 28 78 210 227 1404 
 
               
 
 +ve% 23 22 22 11 10 7 6 5 3 7 18 22 13 
 
               
 
 
 
 57  
Figure IX 
Malaria Blood Film Positive Rates 2004/2005 
A- KSC Hospital Laboratory 
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Table  VIII 
Malaria Prevalence and Positive Rates (2004/2005) 
B-Site Health Centre 
 
Month Nov. Dec. Jan. Feb. March April May June July August Sept. Oct. Total 
 
Diagnosis 2004 2004 2005 2005 2005 2005 2005 2005 2005 2005 2005 2005 2004/05 
 
                             
BFFM 811 1171 766 997 1023 1118 1053 1079 1283 1565 1499 1783 14148 
 
               
 
 +ve 111 147 133 118 37 17 10 31 35 36 159 354 1188 
 
               
 
 +ve% 14 13 17 12 4 2 1 3 3 2 11 20 8 
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Figure X 
Malaria Blood Film Positive Rates 2004/2005 
B - KSC - Site Health Centre 
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Table  IX 
Malaria Blood Film Positive Rates 2004/2005 
C- KSC - Factory Health Centre 
Month Nov. Dec. Jan. Feb. March April May June July August Sept. Oct. Total  
Diagnosis 2004 2004 2005 2005 2005 2005 2005 2005 2005 2005 2005 2005    
                             
BFFM 95 112 131 306 292 199 106 95 164 228 216 210 2154  
                
 +ve 41 43 39 74 69 32 24 11 27 30 54 60 504  
                
 +ve% 43 38 30 24 24 16 23 12 16 13 25 29 23  
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Figure XI 
Malaria Blood Film Positive Rates 2004/2005 
C- KSC - Factory Health Centre 
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3.5   Part II:  Economical impact of malaria in KSC  
Referring to the cost of 50 patients in each group (group I, II, III) the 
cost of the whole patient in the groups was calculated. (Table I) 
 
Group I:   
The inpatient (employees) number registered in 2004/2005 was 310.  
Their cost was found to be  3.17 %. from the health services budget 
(HSB) 2004/2005  (Table  I) 
Group II:   
The cost of 1449 total employees families inpatient in 2004/2005 
represents  5.77 %  from the HSB.  (Table  1) 
Group III:   
The cost of (29000) outpatient in 2004/2005  was found to be 10.54 %  
from HSB (Table I & VII) 
Absenteeism cost:  
(Working days lost due to malaria).  This cost reflects the financial 
impact, which reached 24.7% from the 310 in-patient employees payroll 
and 1.26% from  payroll  2004/2005. (Table II). 
The total malaria cost for the three groups including the absenteeism 
cost was found to be in SDD 115,961,854.27 which makes 13.5% from 
the payroll and 21.75% from the (HSB) (Table II & III) 
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A)   Table (X): malaria economical impact calculation 
 
Description No of 
patient 
2004 – 
2005 
Cost of 50
Patients SD
Cost of group MCC/Citizen. 
SDD 
MCC/group Total Patients 
Cost 
2004/2005 
Budget 
% from 
budget 
 
Group   I 
 
310 2,712,690.00
 
16,818,678.00
 
96270.50 16,914,948.50
 
3.17% 
 
 
Group   II 
 
1449 1,044,859.20
 
30,280,019.62
  
 
449986.95 30,730,006.57
 
5.77% 
 
 
Group   III 
 
29000 81,375.50
 
47,197,790.00
 
9,005,950.00 56,203,740.00
 
10.54% 
 
 
Total 
 
30759 3,838,654.70
 
94,296,487.62
 
 
 
 
310.55 
 
9,535,290.00 103,831,777.62
 
 
 
 
533,258,000 
 
19.47% 
 
 
MCC/citizen = Malaria Combat Cost /Citizen 
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b)   Table XI:  Malaria Absenteeism Cost  in Kenana Sugar Company 2004/2005 
 
No of patient Cost of Abs + opportunity 
SDD 
Payroll cost per year 
SDD 
Manpower 
 
Payroll 
Budget SDD 
% of payroll 
 
50 
 
310 
 
1,726,289.50 
 
10,702,994.90 
 
69,855,358.50 
 
43,3103,322.00 
 
6084 
 
850 000 000 
 
1.26% 
 
24.7% 
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Table (XII) 
Employees (In-Patient) Cost (SD) 
 
Pat No. Inc/day H .day Ex day Abs.day Abs. Cost Effec. Cost H. Cost/day Hos.Cost Treat.Cost H. Total Cost Total Cost 
1 5,000.00 7 7 14 70,000.00 70,000.00 4,933.30 34,533.10 22,415.20 56,948.30 196,948.30 
2 5,000.00 6 7 13 65,000.00 65,000.00 4,933.30 29,599.80 5,726.73 35,326.53 165,326.53 
3 930.90 2 5 7 6,516.30 6,516.30 4,933.30 9,866.60 5,809.00 15,675.60 28,708.20 
4 1,955.83 3 7 10 19,558.30 19,558.30 4,933.30 14,799.90 3,785.40 18,585.30 57,701.90 
5 1,315.43 2 5 7 9,208.01 9,208.01 4,933.30 9,866.60 3,983.00 13,849.60 32,265.62 
6 1,840.50 2 5 7 12,883.50 12,883.50 4,933.30 9,866.60 5,235.33 15,101.93 40,868.93 
7 1,019.40 2 5 7 7,135.80 7,135.80 4,933.30 9,866.60 4,792.54 14,659.14 28,930.74 
8 1,503.40 3 5 8 12,027.20 12,027.20 4,933.30 14,799.90 6,492.00 21,291.90 45,346.30 
9 1,646.60 2 5 7 11,526.20 11,526.20 4,933.30 9,866.60 4,814.00 14,680.60 37,733.00 
10 1,772.30 3 7 10 17,723.00 17,723.00 4,933.30 14,799.90 4,695.00 19,494.90 54,940.90 
11 3,673.15 4 5 9 33,058.35 33,058.35 4,933.30 19,733.20 11,674.00 31,407.20 97,523.90 
12 1,050.48 2 5 7 7,353.36 7,353.36 4,933.30 9,866.60 6,054.00 15,920.60 30,627.32 
13 2,060.35 3 5 8 16,482.80 16,482.80 4,933.30 14,799.90 5,827.00 20,626.90 53,592.50 
14 1,553.50 2 7 9 13,981.50 13,981.50 4,933.30 9,866.60 3,009.00 12,875.60 40,838.60 
15 1,770.59 2 7 9 15,935.31 15,935.31 4,933.30 9,866.60 3,957.00 13,823.60 45,694.22 
16 1,237.64 2 5 7 8,663.48 8,663.48 4,933.30 9,866.60 6,359.00 16,225.60 33,552.56 
17 3,603.20 2 5 7 25,222.40 25,222.40 4,933.30 9,866.60 5,398.00 15,264.60 65,709.40 
18 1,524.25 2 3 5 7,621.25 7,621.25 4,933.30 9,866.60 11,770.60 21,637.20 36,879.70 
19 1,641.20 8 7 15 24,618.00 24,618.00 4,933.30 39,466.40 6,265.00 45,731.40 94,967.40 
20 1,465.75 4 7 11 16,123.25 16,123.25 4,933.30 19,733.20 12,583.00 32,316.20 64,562.70 
21 1,590.00 5 7 12 19,080.00 19,080.00 4,933.30 24,666.50 9,077.00 33,743.50 71,903.50 
22 1,768.60 2 5 7 12,380.20 12,380.20 4,933.30 9,866.60 6,568.00 16,434.60 41,195.00 
23 953.50 4 7 11 10,488.50 10,488.50 4,933.30 19,733.20 4,027.00 23,760.20 44,737.20 
24 3,066.96 2 7 9 27,602.64 27,602.64 4,933.30 9,866.60 3,766.00 13,632.60 68,837.88 
25 2,300.60 1 5 6 13,803.60 13,803.60 4,933.30 4,933.30 1,095.00 6,028.30 33,635.50 
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Pat No. Inc/day H .day Ex day Abs.day Abs. Cost Effec. Cost H. Cost/day Hos.Cost Treat.Cost H. Total Cost Total Cost 
26 1,682.63 2 7 9 15,143.67 15,143.67 4,933.30 9,866.60 4,887.00 14,753.60 45,040.94 
27 2,492.00 2 7 9 22,428.00 22,428.00 4,933.30 9,866.60 6,388.00 16,254.60 61,110.60 
28 2,804.80 4 7 11 30,852.80 30,852.80 4,933.30 19,733.20 4,526.00 24,259.20 85,964.80 
29 1,851.90 2 5 7 12,963.30 12,963.30 4,933.30 9,866.60 2,990.00 12,856.60 38,783.20 
30 820.80 3 5 8 6,566.40 6,566.40 4,933.30 14,799.90 2,587.00 17,386.90 30,519.70 
31 1,028.40 3 5 8 8,227.20 8,227.20 4,933.30 14,799.90 1,835.00 16,634.90 33,089.30 
32 1,053.60 3 5 8 8,428.80 8,428.80 4,933.30 14,799.90 8,027.00 22,826.90 39,684.50 
33 2,058.90 3 5 8 16,471.20 16,471.20 4,933.30 14,799.90 7,003.00 21,802.90 54,745.30 
34 2,067.85 2 7 9 18,610.65 18,610.65 4,933.30 9,866.60 2,295.00 12,161.60 49,382.90 
35 2,293.00 2 5 7 16,051.00 16,051.00 4,933.30 9,866.60 5,323.00 15,189.60 47,291.60 
36 912.00 2 7 9 8,208.00 8,208.00 4,933.30 9,866.60 4,422.00 14,288.60 30,704.60 
37 2,038.34 2 7 9 18,345.06 18,345.06 4,933.30 9,866.60 2,553.00 12,419.60 49,109.72 
38 1,374.41 3 5 8 10,995.28 10,995.28 4,933.30 14,799.90 4,662.00 19,461.90 41,452.46 
39 1,144.00 4 7 11 12,584.00 12,584.00 4,933.30 19,733.20 15,474.00 35,207.20 60,375.20 
40 2,897.83 2 5 7 20,284.81 20,284.81 4,933.30 9,866.60 1,043.00 10,909.60 51,479.22 
41 2,022.44 1 5 6 12,134.64 12,134.64 4,933.30 4,933.30 10,323.00 15,256.30 39,525.58 
42 2,412.11 2 7 9 21,708.99 21,708.99 4,933.30 9,866.60 7,682.00 17,548.60 60,966.58 
43 1,835.92 2 7 9 16,523.28 16,523.28 4,933.30 9,866.60 7,911.00 17,777.60 50,824.16 
44 1,758.49 2 7 9 15,826.41 15,826.41 4,933.30 9,866.60 4,157.00 14,023.60 45,676.42 
45 763.09 2 7 9 6,867.81 6,867.81 4,933.30 9,866.60 5,149.00 15,015.60 28,751.22 
46 2,150.76 3 7 10 21,507.60 21,507.60 4,933.30 14,799.90 4,180.00 18,979.90 61,995.10 
47 1,503.40 2 7 9 13,530.60 13,530.60 4,933.30 9,866.60 6,233.00 16,099.60 43,160.80 
48 1,024.94 4 7 11 11,274.34 11,274.34 4,933.30 19,733.20 6,368.00 26,101.20 48,649.88 
49 2,213.50 3 7 10 22,135.00 22,135.00 4,933.30 14,799.90 4,198.00 18,997.90 63,267.90 
50 1,640.30 2 5 7 11,482.10 11,482.10 4,933.30 9,866.60 5,278.00 15,144.60 38,108.80 
Total 95,089.54 139 300 439 863,143.89 863,143.89 4,933.30 685,728.70 300,671.80 986,400.50 2,712,688.28 
Average 1901.79 3 6 9 17263 17263 4,933.30 13,714.57 6,013.44 19,728.01 54,253.77 
STD 919.94 1.37 1.09 2.02 12133.50 12133.50 0.00 6781.07 3717.51 9124.28 30824.36 
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Table (XIII) 
 
Part (II) Group (1 Employees inpatient cost 
Statistics 
 
 Hospital Days Excused Days Absenteeism Days Hospital Cost Treatment Cost 
No of Patient 50 50 50 50 50 
Mean 2.78 6.00 8.78 13615.9 5797.19 
Mode 2 7 9 98866.6 4662.0 
Std. Deviation 1.37 1.59 2.02 6727.39 3461.63 
Minimum 1 3 5 4933.3 491043 
Maximum 8 7 15 39466.4 22415.2 
Sum 139 300 439 680795.4 289859.7 
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Table (XIV) 
Employees' Families in-Patient Cost 
Patient No. Hos.Days Cost/day Hos.Cost Treat.Cost Total Cost  
1 3 4,933.30 14,799.90 3,979.00 18,778.90  
2 3 4,933.30 14,799.90 4,272.00 19,071.90  
3 3 4,933.30 14,799.90 3,595.00 18,394.90  
4 3 4,933.30 14,799.90 3,689.00 18,488.90  
5 4 4,933.30 19,733.20 4,964.00 24,697.20  
6 3 4,933.30 14,799.90 3,582.00 18,381.90  
7 3 4,933.30 14,799.90 3,023.00 17,822.90  
8 3 4,933.30 14,799.90 5,622.00 20,421.90  
9 4 4,933.30 19,733.20 5,047.00 24,780.20  
10 3 4,933.30 14,799.90 2,843.00 17,642.90  
11 3 4,933.30 14,799.90 7,521.00 22,320.90  
12 3 4,933.30 14,799.90 2,968.00 17,767.90  
13 3 4,933.30 14,799.90 3,373.00 18,172.90  
14 4 4,933.30 19,733.20 6,942.00 26,675.20  
15 4 4,933.30 19,733.20 3,882.00 23,615.20  
16 4 4,933.30 19,733.20 1,790.00 21,523.20  
17 4 4,933.30 19,733.20 5,094.00 24,827.20  
18 3 4,933.30 14,799.90 3,212.00 18,011.90  
19 1 4,933.30 4,933.30 3,973.00 8,906.30  
20 4 4,933.30 19,733.20 2,175.00 21,908.20  
21 5 4,933.30 24,666.50 2,051.00 26,717.50  
22 2 4,933.30 9,866.60 4,575.00 14,441.60  
23 3 4,933.30 14,799.90 4,953.00 19,752.90  
24 4 4,933.30 19,733.20 10,256.00 29,989.20  
25 2 4,933.30 9,866.60 5,525.00 15,391.60  
26 5 4,933.30 24,666.50 20,665.00 45,331.50  
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Patient No. Hos.Days Cost/day Hos.Cost Treat.Cost Total Cost
      
27 4 4,933.30 19,733.20 3,465.00 23,198.20
28 3 4,933.30 14,799.90 3,661.00 18,460.90
29 8 4,933.30 39,466.40 5,678.00 45,144.40
30 6 4,933.30 29,599.80 1,917.00 31,516.80
31 4 4,933.30 19,733.20 2,193.00 21,926.20
32 2 4,933.30 9,866.60 2,651.00 12,517.60
33 3 4,933.30 14,799.90 3,944.00 18,743.90
34 2 4,933.30 9,866.60 2,379.00 12,245.60
35 2 4,933.30 9,866.60 3,321.00 13,187.60
36 2 4,933.30 9,866.60 4,116.00 13,982.60
37 3 4,933.30 14,799.90 3,062.00 17,861.90
38 2 4,933.30 9,866.60 2,451.00 12,317.60
39 2 4,933.30 9,866.60 5,249.00 15,115.60
40 4 4,933.30 19,733.20 12,635.00 32,368.20
41 3 4,933.30 14,799.90 3,419.00 18,218.90
42 3 4,933.30 14,799.90 4,449.00 19,248.90
43 3 4,933.30 14,799.90 7,489.00 22,288.90
44 2 4,933.30 9,866.60 2,476.00 12,342.60
45 5 4,933.30 24,666.50 8,353.00 33,019.50
46 3 4,933.30 14,799.90 3,531.00 18,330.90
47 3 4,933.30 14,799.90 3,974.00 18,773.90
48 4 4,933.30 19,733.20 4,738.00 24,471.20
49 3 4,933.30 14,799.90 4,684.00 19,483.90
50 2 4,933.30 9,866.60 6,392.00 16,258.60
Total 164 4,933.30 809,061.20 235,798.00 1,044,859.20 
Average 3.3 4,933.30 16,181.22 4,715.96 20,897.18
STD 1.18 0.00 5,814.99 3,112.51 7,268.84
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Table (XV) 
 
Part (II) Group (II) Employee families (in patient) cost 
 
Statistics 
 
 Hospital Days Hospital Cost Treatment Cost 
No of Patient 50 50 50 
Mean 3.28 16181.22 4715.96 
Mode 3 14799.90 1790 
Std. Deviation 1.18 5814.99 3112.51 
Minimum 1 4933.3 1790.00 
Maximum 8 39466.4 20665.00 
Sum 164 809061.2 235798.00 
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Table (XVI) 
 
Part (II) Group (III) Malaria outpatient 
 
Description Inc/day No of 
Patient 
Admin. cost
of patient/ 
day 
Admin. cost 
of 50 
Patient 
Treatment 
cost 50 
Patient 
Treatment + 
admin. cost 
Of 50 patient
Cost of  total 
malaria pt. 
% 
from 
Bud. 
Cardex clerk 2355 64 36.80 1840.00   (29000)  
Statistic clerk 1522 64 24.00 1200.00     
Medical Ass (Gen) 2647 60 44.12 2206.00     
Med. Ass Pharm 2895 70 29.93 1496.00     
Drug Regist 1522 64 24.00 1200.00     
Med. Card - - 50.00 2500.00     
Lab. Cost - - 500.00 25000.00     
Total   708.85 35442.50 45933.00 81375.50 47197790.00 8.85% 
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DISCUSSION  
 
A knowledge of the extent of resistance in terms of the geographical 
distribution and degree of resistance is important for the selection of 
appropriate control measures and for the development of policies for 
the national use of drugs. For Kenana Sugar Company as a private 
national important investment, the information of health situation of 
Kenana labour and the economic burden of health is of great concern. 
 Therefore this study was conducted at Kenana Sugar Company to 
highlight the prevalence, endemicity, sensitivity to CQ, control and 
the economical impact of plasmodium faliparum malaria. 
4.1    Sensitivity Of Plasmodium  f. To CQ 
The chloroquine sensitivity rate is 78%- 82%, a result which similar to a result of 
a study conducted by Dr Imadeldin Eljack from the Blue Nile Research and 
Training Institute (BNRTI), in Kenana area 1997, where a sensitivity rate of 75% 
was obtained. Annex (5 ) 
However in contrast to this, there was a study conducted at Kosti city 
(White Nile State), according to country plan of action developed by 
National Malaria Controlled Programme and approved by WHO in 
2002, the sensitivity obtained was only 46.7%.   
Annex (6) 
The sensitivity rate of plasmodium falciparum  to CQ in Kenana 
Sugar  Company does not comply with the study of M. of Health at 
different parts of Sudan and hence the withdrawal of CQ in Kenana is 
premature . The  sensitivity of plasmodium  falciparum  to CQ in 
Kenana can be understood if the following aspects are considered: 
- structure of Kenana society, where most of Kenana, citizens 
are literate (Malaria indoor control is easy), 
- welfare of the citizen (balanced nutrition, disease tolerancy), 
- availability of free medical consultation and medical treatment. 
- adequate environmental health care, 
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- good quality and control of medicine (storage of medicines) 
The sensitivity rate in Kenana is reasonable comparing with other 
parts of Sudan. It justified further treatment with CQ, especially by 
children when the new combination regimen (Artusenate) neglects 
this sector of patients (no syrup form), hence, chloroquine syr. 
Remains the solution of choice if oral palatable antimrial is required 
and the sulphonamide allergy is to be avoided. The sensitivity of CQ 
can be improved to give the maximum by means of the following:  
+ more weight on malaria control strategy,  
+clinical trial on CQ combination therapy with other 
anti-malarials. 
+ indiscriminate and uncontrolled use of drugs should be 
prevented 
+ training of laboratory staff for better performance 
+ development of laboratory diagnostic methods and 
subsidize the new non-microscopic methods (ICT..PCR.. 
etc….). 
The plasmodium f. malaria which  makes 20%from other diseases  
has a peak of high positive rate from September to March, the rainy 
season and the period of the crush season (sugar cane harvest), when 
flux of work demanders are rushing to Kenana in thousands. As they 
come from different parts of the country, some of them might be 
classified as plasmodium species carrier or reservoir. The lower 
period is from April to August, (dry and hot months), when the 
season ends and the temporary labours leave Kenana. This picture is 
coincide with the malaria in-patient profile. Table (VII, VIII & IX). 
The maximum positive BF is not exceeding an average of 14.7% 
from the demanded BF for malaria per year. A discrepancy, which 
can be explained as follows: 
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• Malaria diagnoses is sometimes difficult for non trained staff. 
• The clinical malaria is sometime ambiguous. 
• The BF done where parasite disappear from peripheral blood. 
• Exclusion therapy: malaria can be excluded by cheep and easy 
BF where other diseases  like Enterica and Bruealla diagnoses 
are expensive and time consuming. 
 Nevertheless if this BF is not done the consequence  would be 
worth, hence, indistinct treatment with anti malarial has its 
negative effect on the patient and might hide other diseases. 
As Kenana being an irrigated area with vast pools and much drain 
water, gives a suitable breeding conditions for mosquito. The 
control of malaria needs great effort and facilities. Some 
precaution might reduce the prevalence rate of malaria like: 
*  Periodically spraying of insecticides.  
*  Using impregnated mosquito nets for vulnerable persons. 
*  Environmental management: 
-Drainage of march water (recycling of drain water and the 
hydro flow of irrigation system in Kenana), 
-Flushing of water ways, 
-Cleaning of weed growth, 
-Immerse stagnant water surface with oil, 
* Provoke of acquire immunity by treating only the malaria 
positive cases.  
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4.2   Economical Impact 
 The cost of malaria is a burden on the company budget, where 
the company pays treatment, hospitalization and even the 
absenteeism cost. This exemption from medical fees for Kenana 
employees led to the high malaria frequency, which indicates and 
improved treatment seeking behavior and prompt early diagnosis, 
Many studies had touch the problem of malaria economical impact 
from asocial-economical side and no study was followed the standard 
method of estimation which has to sum the direct cost of expenditure 
on prevention and treatment, and the indirect cost of productive 
labour time lost (Chima, Goodman, Mills 2003). 
This study is the first study conducted in Kenana for determination of 
economical impact of malaria followed the standard method of 
estimation. And as far as can be ascertained no similar study has been 
conducted in this field, and no similar publication was found neither 
in National Centre for Research, nor in Malaria Combat Directorate 
in Khartoum. 
 The result showed that malaria, which makes around 20% from 
the whole diseases in the area, utilized approximately 22% from the 
annual medical budget. (Table I part II). 
- Group I (employees-inpatient) as a productive sector makes only 
17% from the whole malaria inpatient.  
- Group II (employees families) as non-productive sector makes 
83% from the whole malaria inpatient.  This is because the 
number of the families is greater than employee’s number. 
- Group I which makes 17% from inpatient utilize 3.17% from the 
medical budget, where group II (83%) utilize 5.77%.  This is a 
reasonable cost for the company because group I is economically 
most important than group II. 
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- The malaria cost is calculated where chloroquine & quinine were 
used for malaria treatment (as cheap drugs).  The new protocol of 
malaria (artesunate , coartom) which is going to be applied soon, 
will raise this cost at least 15x (unless is issued free or at least 
subsidized) 
Group III (The malaria out patient), which has a frequency of 29000 
per year 2004/05, is 90x group (I) and 20x group (II) even though 
they utilize only 10.97% from the medical budget.  (Table  I part II) 
This is due to the fact that out patient cost is always less than 
inpatient cost. 
The absenteeism caused by malaria makes 2.4% from the payroll per 
year, which is a real lost for the company comparing with the health 
service budget 2004/2005 which was 5.8% from the payroll. 
Comparing the three groups concerning the mean cost of hospital and 
treatment as well as the hospital days, the following result is 
obtained: 
a) Mean hospital cost of group II is higher than group I and III, 
because it’s mean hospital days is higher than group I and III. 
b) Mean treatment cost by group I is higher than group II and III, 
because this group is the employees group where group II is the 
families of the employees that means: 
Children, student, and housewife’s, the recovery by children and 
student is mostly faster than adult, and the therapy according to 
the age is reduced (quinine, artemether or infusions). 
c) Group III comes in the bottom of the cost, because of the short 
stay and simple malaria treatment. 
The cost of malaria combat per year (2004-2005) estimated by 
Kenana environmental health service reached 21.34% from the 
environment health service budget. This percentage must be 
increased to combat such an economically important disease. 
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5.1 Conclusion: 
 
 
 This study was conducted in Kenana Sugar Company health 
centers and hospital to estimate the sensitivity rate of plasmodium f. 
to chloroquine which was found to be 78-82% and to determine the 
economical impact of malaria on the company. 
The general prevalence profile of malaria was observed from 
different aspects e.g. endemicity, diagnoses, manifestation & 
treatment, drug resistant, control of malaria, immunity in malaria and 
vaccination. 
The economical impact of malaria was determined at hand of the cost 
of three groups of patient (out and in-patient), which represents the 
employees and their families. 
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5.2 Recommendation: 
 
 
Chloroquine is still an effective drug particularly in Kenana and it 
can be used as first line drug for the treatment of simple plasmodium 
falciparum malaria.  
-  A treatment guideline protocol in Kenana hospital must be 
established to have the highest sensitivity rate of Plasmodium 
falciparum to Chloroquine.  
-    New anti-malarial drugs must be kept as reserve malaria therapy. 
-  More weight should be given to the health education to minimize 
the high hospital frequency rate of Kenana people. 
-    The modernization of medical laboratories and continuous 
training of laboratory Staff should be a Kenana strategy for better 
diagnostic performance. Moreover, the new malaria diagnostic 
methods like ICT, PCR…etc., have to be generalized (cost 
effectiveness).  
Annual research of malaria in different areas and categories has to be 
the strategy of Kenana and a national malaria control department. 
Result of malaria prevalence from Kenana health centers have to be 
discussed an evaluated every month.   
The health centers need to be provided with better equipped 
laboratories for early detection of malaria. 
Environmental health: This sector should be financially supported to 
give the highest control level of mosquito. 
Impregnated mosquito nets should have been used in great scale. This 
might positively effect the parasite life cycle. 
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Annexes 
 
 
1. Antimalaria drugs certificate of analysis.(10) 
2.  Treatment form of malaria at kenana health centers 
3. Malaria treatment result form in Kenana health centers  
(Table I – IV) 
4. Malaria cost ( Group 111 out-Patient). 
5. Chloroquine failure in different areas in Sudan (Malaria 
Central Directorate) 
6. Kenana malaria combat cost 2004/2005) 
7. Kenana Malaria drugs price comparison 2004/2005 
8. Antimalarial drugs consumption in Kenana 2000/2005 
9. Study of Dr. Imad Eldin in Kenana (CRM) 1997. 
10. Hospital cost calculations 
